NZ618651B2 - Expansion of stem cells in hollow fiber bioreactors - Google Patents
Expansion of stem cells in hollow fiber bioreactors Download PDFInfo
- Publication number
- NZ618651B2 NZ618651B2 NZ618651A NZ61865112A NZ618651B2 NZ 618651 B2 NZ618651 B2 NZ 618651B2 NZ 618651 A NZ618651 A NZ 618651A NZ 61865112 A NZ61865112 A NZ 61865112A NZ 618651 B2 NZ618651 B2 NZ 618651B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cells
- cell
- hollow fiber
- stem
- embryonic
- Prior art date
Links
- 239000012510 hollow fiber Substances 0.000 title claims description 127
- 210000000130 stem cell Anatomy 0.000 title description 69
- 210000004027 cells Anatomy 0.000 claims abstract description 494
- 239000000835 fiber Substances 0.000 claims abstract description 45
- 210000004602 germ cell Anatomy 0.000 claims abstract description 37
- 102000004591 Telomerase Human genes 0.000 claims abstract description 15
- 108010017842 Telomerase Proteins 0.000 claims abstract description 15
- 239000000758 substrate Substances 0.000 claims abstract description 14
- 238000010899 nucleation Methods 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims description 31
- 101710026246 POU5F1 Proteins 0.000 claims description 25
- 210000001519 tissues Anatomy 0.000 claims description 24
- 150000002500 ions Chemical class 0.000 claims description 12
- 108010067306 Fibronectins Proteins 0.000 claims description 11
- 102000016359 Fibronectins Human genes 0.000 claims description 11
- 230000037320 fibronectin Effects 0.000 claims description 11
- 210000004700 Fetal Blood Anatomy 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 9
- 210000002826 Placenta Anatomy 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 8
- 210000004556 Brain Anatomy 0.000 claims description 7
- 210000004369 Blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 210000003205 Muscles Anatomy 0.000 claims description 5
- 101700006931 SOX2 Proteins 0.000 claims description 5
- 239000011886 peripheral blood Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- -1 rox-1 Proteins 0.000 claims description 5
- 210000000988 Bone and Bones Anatomy 0.000 claims description 4
- 210000003954 Umbilical Cord Anatomy 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000003169 placental Effects 0.000 claims description 3
- 229920000110 poly(aryl ether sulfone) Polymers 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 210000003734 Kidney Anatomy 0.000 claims description 2
- ZHXISMXDCUJVCY-UHFFFAOYSA-N 2-phenylsulfanylethanamine;hydrochloride Chemical compound [Cl-].[NH3+]CCSC1=CC=CC=C1 ZHXISMXDCUJVCY-UHFFFAOYSA-N 0.000 claims 1
- 241000048284 Potato virus P Species 0.000 claims 1
- 101700068938 ZFP42 Proteins 0.000 claims 1
- 238000001637 plasma atomic emission spectroscopy Methods 0.000 claims 1
- 101700033684 rex Proteins 0.000 claims 1
- 230000010261 cell growth Effects 0.000 description 56
- 239000002609 media Substances 0.000 description 52
- 235000015097 nutrients Nutrition 0.000 description 35
- 210000001185 Bone Marrow Anatomy 0.000 description 31
- 239000002699 waste material Substances 0.000 description 30
- 239000012528 membrane Substances 0.000 description 29
- 210000004379 Membranes Anatomy 0.000 description 26
- 102100019163 POU5F1 Human genes 0.000 description 24
- 239000012530 fluid Substances 0.000 description 22
- 239000000203 mixture Substances 0.000 description 19
- 241000282414 Homo sapiens Species 0.000 description 18
- 239000000306 component Substances 0.000 description 18
- 238000004113 cell culture Methods 0.000 description 17
- 230000004069 differentiation Effects 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 17
- 230000012010 growth Effects 0.000 description 16
- 239000011148 porous material Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 13
- 210000001736 Capillaries Anatomy 0.000 description 11
- 230000001464 adherent Effects 0.000 description 11
- 230000035492 administration Effects 0.000 description 11
- 210000001082 somatic cell Anatomy 0.000 description 11
- 210000001654 Germ Layers Anatomy 0.000 description 10
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 210000002966 Serum Anatomy 0.000 description 9
- 230000001058 adult Effects 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- 238000003306 harvesting Methods 0.000 description 9
- 210000002459 Blastocyst Anatomy 0.000 description 8
- 239000004952 Polyamide Substances 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 229920002647 polyamide Polymers 0.000 description 8
- 239000011528 polyamide (building material) Substances 0.000 description 8
- 210000001178 Neural Stem Cells Anatomy 0.000 description 7
- 230000001413 cellular Effects 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 7
- 102000003995 transcription factors Human genes 0.000 description 7
- 108090000464 transcription factors Proteins 0.000 description 7
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 6
- 210000002901 Mesenchymal Stem Cells Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000001965 increased Effects 0.000 description 6
- 238000004382 potting Methods 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 210000004940 Nucleus Anatomy 0.000 description 5
- 206010043276 Teratoma Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 210000004271 bone marrow stromal cells Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002708 enhancing Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000001963 growth media Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000000392 somatic Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000004504 Adult Stem Cells Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101710042158 GYPA Proteins 0.000 description 4
- 102100011618 GYPE Human genes 0.000 description 4
- 101710042157 GYPE Proteins 0.000 description 4
- 210000004263 Induced Pluripotent Stem Cells Anatomy 0.000 description 4
- 210000003716 Mesoderm Anatomy 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 102000014961 Protein Precursors Human genes 0.000 description 4
- 108010078762 Protein Precursors Proteins 0.000 description 4
- 108090001123 antibodies Proteins 0.000 description 4
- 102000004965 antibodies Human genes 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000003394 haemopoietic Effects 0.000 description 4
- 230000000051 modifying Effects 0.000 description 4
- 238000010449 nuclear transplantation Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 4
- 230000003068 static Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 102100010813 EGF Human genes 0.000 description 3
- 101700033006 EGF Proteins 0.000 description 3
- 210000002304 ESC Anatomy 0.000 description 3
- 210000001900 Endoderm Anatomy 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010022114 Injury Diseases 0.000 description 3
- 241000272168 Laridae Species 0.000 description 3
- 210000004185 Liver Anatomy 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101700059076 PTPRC Proteins 0.000 description 3
- 102100005499 PTPRC Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000001608 Teratocarcinoma Diseases 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 230000000735 allogeneic Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 239000006143 cell culture media Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001143 conditioned Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000002308 embryonic cell Anatomy 0.000 description 3
- 230000001973 epigenetic Effects 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 210000002569 neurons Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 229960001322 trypsin Drugs 0.000 description 3
- 230000000381 tumorigenic Effects 0.000 description 3
- 231100000588 tumorigenic Toxicity 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 210000000845 Cartilage Anatomy 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 2
- 101710027196 FBXO15 Proteins 0.000 description 2
- 210000000265 Leukocytes Anatomy 0.000 description 2
- 102100015262 MYC Human genes 0.000 description 2
- 210000002540 Macrophages Anatomy 0.000 description 2
- 210000000472 Morula Anatomy 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101700003526 SALL4 Proteins 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 210000002536 Stromal Cells Anatomy 0.000 description 2
- 229940035295 Ting Drugs 0.000 description 2
- 230000001070 adhesive Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 101710014509 celF Proteins 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000010192 crystallographic characterization Methods 0.000 description 2
- 230000032459 dedifferentiation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000002257 embryonic structures Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 230000002519 immonomodulatory Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000011068 load Methods 0.000 description 2
- 210000004962 mammalian cells Anatomy 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 239000012533 medium component Substances 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000001537 neural Effects 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 210000004255 neuroglia Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000004886 process control Methods 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000003362 replicative Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- CIWBSHSKHKDKBQ-DUZGATOHSA-N (+)-Ascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SPVPFVKYMAGOSM-XUXIUFHCSA-N (2S)-2-amino-5-[[(2R)-3-[[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-[(2-ethoxy-2-oxoethyl)amino]-3-oxopropyl]disulfanyl]-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CCOC(=O)CNC(=O)[C@@H](NC(=O)CC[C@H](N)C(O)=O)CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O SPVPFVKYMAGOSM-XUXIUFHCSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 210000000577 Adipose Tissue Anatomy 0.000 description 1
- 210000004381 Amniotic Fluid Anatomy 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 0 C=C=C(CC1C(CCC2)NC1)C(C1)CC#CC1C2=* Chemical compound C=C=C(CC1C(CCC2)NC1)C(C1)CC#CC1C2=* 0.000 description 1
- 108060001251 CD34 Proteins 0.000 description 1
- 102100016492 CD34 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 210000004720 Cerebrum Anatomy 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N Chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000020504 Collagenase family Human genes 0.000 description 1
- 108060005980 Collagenase family Proteins 0.000 description 1
- 101700061444 DDX25 Proteins 0.000 description 1
- 102000031025 DNA-Binding Proteins Human genes 0.000 description 1
- 108091000102 DNA-Binding Proteins Proteins 0.000 description 1
- 210000004443 Dendritic Cells Anatomy 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- 101700057458 Drice Proteins 0.000 description 1
- 210000003981 Ectoderm Anatomy 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 210000004494 Erythroblasts Anatomy 0.000 description 1
- 102100007406 FGF4 Human genes 0.000 description 1
- 101700036125 FGF4 Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 241001585258 Heterocampa guttivitta Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 210000004754 Hybrid Cells Anatomy 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 101700048573 KLF4 Proteins 0.000 description 1
- 102100006525 KLF4 Human genes 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 210000003593 Megakaryocytes Anatomy 0.000 description 1
- 230000036091 Metabolic activity Effects 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 210000000933 Neural Crest Anatomy 0.000 description 1
- 210000000948 Non-nucleated cell Anatomy 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 239000004697 Polyetherimide Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 229950008882 Polysorbate Drugs 0.000 description 1
- 210000004129 Prosencephalon Anatomy 0.000 description 1
- 101700079116 QSOX1 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 210000000717 Sertoli cell Anatomy 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- 210000004927 Skin cells Anatomy 0.000 description 1
- 210000000278 Spinal Cord Anatomy 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000003411 Telomere Anatomy 0.000 description 1
- 210000002435 Tendons Anatomy 0.000 description 1
- 229920002803 Thermoplastic polyurethane Polymers 0.000 description 1
- 239000004433 Thermoplastic polyurethane Substances 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N Trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- 210000002993 Trophoblasts Anatomy 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 102100009661 VTN Human genes 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 210000001766 X Chromosome Anatomy 0.000 description 1
- 210000001325 Yolk Sac Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000005550 amino acid supplement Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000012592 cell culture supplement Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 229920002083 cellular DNA Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010372 cloning stem cell Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003636 conditioned culture media Substances 0.000 description 1
- 230000023298 conjugation with cellular fusion Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000000779 depleting Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 201000009051 embryonal carcinoma Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002514 epidermal stem cell Anatomy 0.000 description 1
- 230000000925 erythroid Effects 0.000 description 1
- 230000000763 evoked Effects 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 210000001368 germline stem cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000003897 hepatic stem cell Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000003318 immunodepletion Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 230000002175 menstrual Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 230000007819 multidimensional cell growth Effects 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 238000010373 organism cloning Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 230000002572 peristaltic Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000008943 replicative senescence Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000004017 serum-free culture media Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementation Effects 0.000 description 1
- 230000005700 syncytium formation by plasma membrane fusion Effects 0.000 description 1
- 229920000511 telomere Polymers 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 102000002938 thrombospondin family Human genes 0.000 description 1
- 108060008245 thrombospondin family Proteins 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N β-glycerophosphoric acid Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/08—Bioreactors or fermenters specially adapted for specific uses for producing artificial tissue or for ex-vivo cultivation of tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/06—Tubular
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/16—Microfluidic devices; Capillary tubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/10—Hollow fibers or tubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/10—Perfusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/16—Hollow fibers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M33/00—Means for introduction, transport, positioning, extraction, harvesting, peeling or sampling of biological material in or from the apparatus
- C12M33/04—Means for introduction, transport, positioning, extraction, harvesting, peeling or sampling of biological material in or from the apparatus by injection or suction, e.g. using pipettes, syringes, needles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
Abstract
Disclosed is a method of expanding cells ex vivo, the method comprising the steps of: a) seeding the cells on a hollow fibre substrate so that the cells adhere to the substrate; b) expanding the adhered cells on the substrate; and c) removing the expanded cells from the substrate, wherein the cells are non-embryonic stem, non-germ cells, wherein the cells express telomerase, are not transformed, and have a normal karyotype. are non-embryonic stem, non-germ cells, wherein the cells express telomerase, are not transformed, and have a normal karyotype.
Description
EXPANSION OF STEM CELLS IN HOLLOW FIBER BIOREACTORS
FIELD OF THE INVENTION
The invention is directed to producing large numbers of cells using hollow fiber continuous
ion bioreactor technology. The cells are non-embryonic stem, rm cells that can be
characterized by one or more of the following: extended replication in culture and markers of extended
replication, such as telornerase, markers of pluripotentiality, and broad differentiation potential, without
being transformed.
BACKGROUND OF THE INVENTION
[0002} Hollow fiber bioreactor technology has been used to obtain high density expansion of cells.
Generally, cells are ed in and/or outside of a multitude of hollow fibers. Because of the high surface
area provided by this design, using the fibers as a culture substrate allows the production of large numbers of
cells, especially for clinical applications. This technology, first developed in the 1970s by Knazek, has
undergone numerous developments and improvements. The basic concept is ing a fiber matrix that is
ble to nutrients, gases, and other basic medium components, and to ar waste products, but
which is impermeable to the cells and upon which the cells can expand.
Cell culture on semi-permeable tubular membranes was initially invented by Knazek in the early
19705. See, for example, US. 3,821,087; 3,883,393; 4,220,725; 922; and 4,200,689. In accordance
with that invention, cells suspended in nutrient medium were allowed to settle on the outer es of
capillaries that were continuously perfused by oxygenated nutrient medium flowing through the capillaries.
Nutrient substances diffused from the perfusion medium through the capillary wall and into the cells while
cell waste products diffused from the cells through the capillary wall to the perfusate from which those
products could be recovered.
That technology was developed as a response to failed attempts to grow cells to ies and/or
structures approaching those of living tissue. , there were problems growing viable cells to very high
densities such as to those that are found in s. First, components of the medium must diffuse through
cell layers to reach all cells as the thickness of the cell layer increases Second, a suitable micro-
environment must be maintained during the cell culture. Thus, fluid immediately adjacent to the growing
cells is continuously changing as cellular metabolism proceeds and is returned to its original state only in
step-wise fashion when the culture medium is changed or ed. Third, a lattice or suitable material on
which to grow the dense cells is required. Knazek’s invention solved these problems by providing nutrient.
sources within the cell mass that supply both large and small essential molecules; sinls within the cell mass
remove the ts of metabolism; a le micro-environment; a lattice to permit growth in three
W0 2012/168295
ions; and a surface area for mono- and/or multi-layer cell cultures that is large relative to the volume
required by standard cell culture techniques.
Since the al invention, this technology has been successfully used to expand various cell
of this basic
types and there is large body of scientific and patent literature directed to various improvements
technology. These improvements have dealt with various technical modifications to optimize the use of this
technology to achieve the original goals of Knazek. 1n the industry, this technology has come to be
designated “hollow fiber” cell e and, in a bioreactor setting, es a hollow fiber bioreactor cell
e. See, for example, U.S. Patents 3,997,396; 4,184,922; 4,200,689; 4,220,725; 4,804,628; 4,999,298;
,126,238; 5,162,225; 5,627,070; 5,656,421; 5,712,154; 6,001,585; 6,680,166; 6,911,201; 6,933,144;
609; U.S. Publications 2001/0044413; 200310224510; 2005/0032218; 2005/0003530; 2006/0205071;
2007/0298497; 2008/0206733; 2008/0213894; 2008/0220522; 2008/0220523; 227190; 2008/248572;
2008/254533; 2009/0191631; 2009/0196901; 2010/0042260; 2010/0144037; 2010/0209403; 2010/0233130;
2010/0267134; W0 91/18972; WO 95/13088; WO 95/21911; WO 01/23520; WO 07/012144; W0
/034468; W0 10/149597; and Gloeclcner et al., Biotech Prog 17:828-3] (2001).
U.S. 2010/0267134 discloses the isolation, characterization, and differentiation of adult human
This reference describes growing spermatagonial
germ line stem cells using hollow fiber capillary culture.
stem cells on feeder layers of Sertoli cells that have been seeded onto the hollow fiber capillary surface.
U.S. 2007/0298497 and 2008/0220523 disclose hollow fiber bioreactor technology applied to
hymal stem cells. Cell expansion systems and methods of using them to grow mesenchymal stem
cells are bed.
U.S. 2009/0196901 relates to methods and systems for facilitating growth and differentiation of
adipose—derived stem cells. The cells can be grown with a ically-compatible ld structure that
cultured in a bioreactor
may comprise hollow fibers for cell growth and differentiation, the ld being
for growth and entiation of the cells. The reference suggests that other stem cell types may be used in
this process. However, prior to growth and differentiation on the woven fiber ld for culture in the
bioreactor, the cells have been expanded significantly in cell culture already. This produces a ent
number of stem cells so that the cells can be concentrated and suspended in a matrix such as a gel
biomaterial and applied to the three-dimensional scaffold.
U.S. 2010/0209403 discloses s for growing adherent placental and adipose mesenchymal
stem cells in bioreactors that can se hollow fibers.
W0 95/13088 discloses hollow fiber technology for growing hematopoietic stem cells with stromal
cell support.
PCTlEP20lZ/060690
[00.11] W0 91/] 8972 discloses hollow fiber bioreactors for growing hematopoietic stem cells from bone
marrow.
W0 07/012144 discloses hollow fiber bioreactors that are ed by attaching linkers to the
surface to propagate embryonic stem cells and other cells.
W0 10/149597 discloses hollow fiber bioreactors for growing spennatagonial and other germ line
cells.
W0 10/034468 discloses hollow fiber technology in which adherent cells are grown without a
coating, for example, mesenchymal stem cells.
Antwiler et al.(“Bioreactor Design and entation,” Stem Cell Bioengineering, Parekkadan
and Yarmush, eds, pp. 49-62 (2009)) discloses a method for the ex vivo expansion of hymal stem
cells from both bone marrow mononuclear cells and whole bone marrow using an automated hollow fiber
bioreactor system. The system sed a synthetic hollow fiber ctor connected to sterile closed-
loop computer-controlled media and gas exchangers. In experimental gs, this allowed therapeutic
doses of mesenchymal stem cells to be grown from small amounts of single bone marrow tes within a
relatively short amount oftime.
SUMMARY OF THE INVENTION
The present invention relates to expanding the cells described herein in hollow fiber bioreactors.
uous perfusion for continuous feed of nutrients and removal of waste metabolites is an aspect of the
invention. Collection of desired secreted les is also an aspect.
The cells may be expanded directly from a tissue sample, for example, from bone marrow, cord
blood, or placenta, as Impurified or partially-purified ations. Or the cells may be a d preparation
of cells that are substantially homogeneous, having been previously isolated and expanded or otherwise
purified. Thus, the purity of the starting cell preparation may be virtually unpurified (such as starting with
total bone marrow mononuclear cells) or from 1%»100% pure. In some embodiments the purity of the cells
for administration to a subject is about 100% (substantially homogeneous). In other embodiments it is 95%
to 100%. In some embodiments it is 85% to 95%. However, the percentage can be about l%-5%, ,
%-15%, 15%-20%, 20%—25%, 25%-30%, 30%-35%, 35%-40%, 40%—45%, 45%-50%, 60%-70%, 70%-
80%, 80%—90%, or 90%—95%. Or isolation/purity can be expressed in terms of cell doublings where the
cells have undergone. for example, 10—20, 20-30, 30-40, 40-50 or more cell doublings.
W0 2012/168295
The cells may be derived from a single donor for expansion and return to that same donor
(autologous). Or the cells may be derived from a single donor for expansion and administration to a
different subject (allogeneic). Or the cells may be derived from different donors.
The cells may be expanded (proliferated) through any desired number of cell doublings. Ranges
include from two—fold up to 1000-fold or more. The limit will depend 0n the capacity to provide sufficient
nutrients and remove rious waste. In some embodiments, cell doubling is in the range of about 2-
about 10 fold, about 10- about 50 fold, and about 50- about lOO—fold. Using the technology described in this
application, greater than 108 cells can be produced from a single donor.
Cells may be expanded, ted, and then re—introduced into the ctor for further expansion
For the purposes of this application, a “run” refers to one round of expansion (from introduction of the cells
to harvesting). Accordingly, cells may be collected afler one or more than one run. A “passage” refers to a
run. Cells may be expanded through different cell doublings in each run. In a single run, for example, cells
may expand two-tenfold. However, with repeated runs, the total expansion may be much higher (as
discussed above).
The cells to which the invention is ed may express pluripotency markers, such as oct4. They
may also express markers associated with extended replicative ty, such as telomerase. Other
characteristics of pluripotency can e the ability to differentiate into cell types of more than one germ
layer, such as two or three of ectodennal, endodermal, and mesoderrnal embryonic germ layers. Such cells
t being
may or may not be immortalized or transformed in culture. The cells may be highly expanded
transformed and also maintain a normal karyotype. For example, in one embodiment, the non-embryonic
stem, non-germ cells may have undergone at least 10—40 cell doublings in culture, such as 50, 60, or more,
wherein the cells are not transformed and have a normal karyotype. The cells may differentiate into at least
one cell type of each of two of the endodennal, ectodermal, and mesoderrnal embryoaic lineages and may
include differentiation into all three. Further, the cells may not be tumorigenic, such as not ing
teratomas. If cells are transformed or tumorigenic, and it is desirable to use them for infusion, such cells
may be disabled so they cannot form tumors in vivo, as by ent that prevents cell proliferation into
tumors. Such ents are well known in the art.
Cells include, but are not limited to, the following numbered ments:
1. Isolated ed non—embryonic stern, non-germ cells, the cells having undergone at least 10-
40 cell doublings in culture, wherein the cells express oct4, are not ormed, and have a normal
karyotype.
2. The non—embryonic stern, non—germ cells of ] above that further express one or more of
telomerase, rex—l, rox-l, or sex-2.
3. The non-embryonic stem, non-germ cells of 1 above that can differentiate into at least one cell
type of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages.
4. The non-embryonic stem, non-germ cells of 3 above that further express one or more of
telomerase, rex-l, rox-l, or sort-2.
5. The non-embryonic stem, non—germ cells of 3 above that can differentiate into at least one cell
type of each of the endodermal, ectodermal, and mesodennal embryonic lineages.
6. The non-embryonic stem, non-germ cells of 5 above that further express one or more of
telomemse, tex-l, rox-l, or sox—2.
7. Isolated expanded non—embryonic stem, non-germ cells that are obtained by culture of non-
embryonic, rm tissue, the cells having undergone at least 40 cell doublings in e, wherein the
cells are not transformed and have a normal karyotype.
8. The non-embryonic stem, non-germ cells of 7 above that express one or more of oct4,
rase, rex-I, rox-l, or sex-2.
9. The non-embryonic stem, non»germ cells of 7 above that can entiate into at least one cell
type of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages.
10. The non-embryonic stem, non-germ cells of 9 above that express one or more of oct4,
telomerase, Tex-1, rox-l, or sort-2.
11. The non—embryonic stem, non—germ cells of 9 above that can differentiate into at least one cell
type of each of the endodermal, ectodennal, and mesodermal embryonic lineages.
12. The bryonic stem, non-germ cells of 11 above that s one or more of oct4,
telomerase, rex-l, rox-l, or sox—2.
13. Isolated expanded non-embryonic stem, non-germ cells, the cells having undergone at least 10-
40 cell doublings in culture, n the cells express telomerase, are not transformed, and have a normal
karyotype.
14. The non-embryonic stem, non-germ cells of 13 above that r express one or more of oct4,
rex-l, rox—l, or sox-2.
15. The non-embryonic stem, non-germ cells of l3 above that can differentiate into at least one
cell type of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages.
W0 2012/168295
16. The non—embryonic stem, non-germ cells of 15 above that further express one or more of oct4,
rexml, rox-l, or sort—2.
17. The non-embryonic stem, non-germ cells of 15 above that can differentiate into at least one
cell type of each of the endodermal, ectodermal, and rmal embryonic lineages.
18. The non-embryonic stem, non»germ cells of 17 above that further s one or more of oct4,
rex—l, rox—l, or sox-Z.
19. Isolated expanded non-embryonic stem, non—germ cells that can differentiate into at least one
cell type of at. least two of the endodermal, ectodermal, and mesodermal embryonic lineages, said cells
having undergone at least 10-40 cell doublings in e.
20. The non-embryonic stem, rm cells of 19 above that express one or more of oct4,
telomerase, rcxwl, rox-l, or sax-2.
21. The non-embryonic stem, non-germ cells of 19 above that can differentiate into at least one
cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages.
22. The non-embryonic stem, non-germ cells of 21 above that express one or more of oct4,
telomerase, rex-l, rox-l, or sax-2.
The cells described above can be ed from any desirable tissue source, including, but not
limited to, bone marrow, cal cord blood, cal cord matrix, peripheral blood, placenta, placental
blood, muscle, brain, kidney, and other solid organs. They can also be derived from excreted fluids, such as
urine and menstrual blood.
In one embodiment, the cells are derived from human tissue.
In configuring the hollow fiber ctor, there are several design considerations and several
of the cells.
parameters that can be varied depending upon the goals associated with expansion First, the
number of fibers in the ctor can be varied. A plurality or bundle of fibers is generally used to e
a desired surface area and a high density of cells. cal ranges in the number of fibers will also vary
depending upon the length of the fibers. Thus, the length is also variable. Generally, the length of the fibers
is only limited by the ability to efficiently move nutrient medium into contact with the cells, remove waste
substrate.
or desired cellular products, and to effectively release the cells from the fiber ingly, the
consideration is the thickness of the fiber wall.
range in the length of the fibers can vary. A further design
The wall thickness is variable and is limited only by the parameters of efficiently providing nutrients to the
cells and efficiently removing waste or useful products from the cells. Another design consideration is the
size of the pores in the fiber wall. This is generally designed to allow the passage of nutrients to the cells,
carry away waste, provide desired products to the cells (such as growth factors), to remove desired products
from the cells, and the like. For example, pore size can be designed to exclude certain factors that may be
present, for example, in serum, from reaching the cells. A further design consideration is the inner
dimension of the hollow fibers (such as the er of a round fiber). Considerations for this choice
include adequate access of the culture medium to the cell, to provide te nutrients, remove waste, and
to achieve desired cellular densities. A further design consideration is the composition of the fiber wall.
This includes a wide variety ofbio-compatiblc materials that e a substrate on which cells can adhere.
In some embodiments, nce may be improved by coating the wall material with an adherence-
ing substrate, such as an extracellular matrix protein.
Furthermore, more than one type of fiber may be found in the bioreactor with respect to the various
parameters described above. This is useful, for e, when it is desirable to ture ent cell
types. Optimal fiber design may differ for the different cells.
The plurality of hollow fibers is generally encased in an outer shell that is desirably connected to
inlet and outlet ports for perfusing medium into and/or around the fibers. In one embodiment, these fibers
are found as part of a growth chamber in which cell medium is perfused (circulated) so that medium flows in
and/or around the fibers. In one embodiment, the fibers are placed in a cartridgethat is connected to a pump
for infusion of cell culture medium and supplements.
The als of which the fibers can be made comprise a large variety of bio-compatible semi-
permeable materials. Such materials permit cell growth in three dimensions while allowing nutrient medium
to diffuse through the fiber walls to feed the cells.
The cells to which the invention is directed may be co-cultured with other cell types with which
they are co-plated or which have been separately adhered or otherwise ed in the expansion chamber.
In one embodiment, the other cells may be attached to the interior (or exterior) surface of the fiber prior to
introducing the cells of the invention. Accordingly, the cells of the invention may be deposited on a
monolayer of a ble cell type.
The hollow fibers can be pre-coated with one or more extracellular matrix proteins, for example,
Matrigel, fibronectin, or en, to enhance cell attachment. Extracellular matrix proteins may be attached
to the internal and/or external surface of the fibers. lly, extracellular matrix protein may be attached
to the surface by any of the methodologies as described in U.S. Pat. No. 5,872,094 and U.S. Pat. No.
6,471,689, both ofwhich are incorporated herein by reference for teaching these methodologies.
Flow rates are also variable depending upon the cells to be expanded and the stage of the process.
For example. after achieving cell adhesion, after cell inoculation, the flow rate can be increased to a steady-
PCT/EP2012l060690
state level. The rate would be increased after the adherence of the cells and again to facilitate the harvesting
of the cells from within the chambers.
A custom-designed hollow-fiber capillary culture system could be ctured using readily
available materials for mammalian cell e on a contractual basis by many different vendors. Some types
of hollow-fiber systems for cell culture are commercially ble from companies, for example, FiberCell
Systems, Inc. rick, Md.). The hollow fiber systems made by FiberCell Systems are composed of fibers
that are imately 200 microns in er. The fibers are sealed into a cartridge that is designed so that
cell e medium pumped through the end of the cartridge flows through the inside of the fiber. The cells
are attached to a porous support and the cultures can be maintained for many months of continuous
production.
Analysis of expanding/expanded cells may include expression of markers such as those described
in this application. In addition, the lack of expression of hematopoietic markers such as CD34 and CD45
may be ed. The sample supernatant and monolayers can be ically monitored for (a) cell
morphology, (b) ploidy and (c) in situ hybridization for cell markers.
As indicated above, cells that are expanded in the bioreactor may first be isolated and cultured
using other culture conditions. For e; the exemplified cells (designated “MAPC”) may be first
isolated and cultured as described herein below.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 provides a schematic illustration of a hollow fiber cell expansion system.
Figure 2 is a schematic view of a bioreactor that may be used in this invention.
Figure 3A depicts a side View of a hollow fiber cell growth chamber embodiment of a cell growth
chamber. Figure 3B depicts a cut-away side view of the hollow fiber cell growth chamber of the
embodiment of Figure 3A.
Figure 4 — A cell expansion system (CBS) fluid circuit showing block diagram system and all bag
connections.
Figure 5 — Flow scheme for Quantum Cell Expansion System from Caridian BCT (now owned by
Terumo) used to expand MultiStem from bone marrow or from cell banks.
Figure 6 — A whole bone marrow aspirate was seeded in the Quantum without prior ion of the
bone marrow mononuclear cells (BMMNC) and BMMNC from the same donot were seeded on regular cell
culture c. This was done for 3 independent donors. Cells inthe T75 were passaged at least 3 times and
PCT/EP2012l060690
cell numbers Were d to calculate the population doubling- (PD). Cells in the Quantum were harvested,
counted, loaded onto a. new bioreactor and harvested again 6 days later. Expansion rate for MultiStem
starting from a bone marrow te in the Quantum are not significantly different from expansion on cell
culture plastic.
Figure 7 - Starting from a bone marrow aspirate, it is possible to create a MultiStem master cell
bank within 17 days.
Figure 8 - More detailed scheme of apparatus of Figure 5.
Figure 9 — Overw‘ew of an expansion embodiment with the closed system. continuous perfusion,
hollow fiber bioreactor.
Figure 10- Overview of the production proceSS, from isolating the cells from a qualified donor to
creating a mayor cell bank, and then administering the cells to a t.
Figure 11- tic of cell banking approach.
DETAILED DESCRIPTION OF THE INVENTION
It should be tood that this invention is not limited to the particular methodology, protocols,
and reagents, etc., described herein and, as such, may vary. The terminology used herein is for the e
of describing ular embodiments only, and is not intended to limit the scope of the sed invention,
which is defined solely by the claims.
The section headings are used herein for organizational purposes only and are not to be ued
as in any way limiting the t matter described.
The methods and techniques of the present application are generally performed according to
conventional methods well-known in the art and as described in various general and more specific references
that are cited and discussed throughout the present specification unless otherwise indicated. See, e.g.,
Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, NY. (2001) and Ausubel et a1., Current Protocols in Molecular y, Greene
Publishing Associates (1992), and Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, NY. (1990).
Definitions
“A” or “an” means herein one or more than one; at least one. Where the plural form is used herein,
it generally includes the singular.
PCT/EP20121060690
The term “bioreactor” refers to a cell culture system that provides nutrients to cells and removes
metabolites, as well as furnishes a physio-chemical environment conducive to cell growth, in a closed sterile
system.
As used herein, the term "bioreactor" refers to any device in which biological and/or biochemical
processes develop under monitored and controlled environmental and operating conditions, for example, pH,
temperature, pressure, nutrient supply and waste removal. ing to the invention, the basic class of
bioreactors suitable for use with the present invention includes hollow fiber bioreactors.
A “cell ba ” is industry nomenclature for cells that have been
grown and stored for future use.
Cells may be stored in aliquots. They can be used directly out of storage or may be expanded after storage.
This is a ience so that there are “off the shelf" cells available for stration. The cells may
already be stored in a phannaceutically—acceptable excipient so they may be directly administered or they
may be mixed with an appropriate excipient when they are released from storage. Cells may be frozen or
otherwise stored in a form to preserve ity. hi one embodiment of the invention, cell banks are created
in which the cells have been ed for enhanced modulation of activation of macrophages. Following
release from storage, and prior to administration to the subject, it may be preferable to again assay the cells
for y, i.e., level of modulation of activation of macrophages. This can be done using any of the
assays, direct or indirect, described in this application or otherwise known in the art. Then cells having the
desired potency can then be administered to the subject for treatment. Banks can be made using cells
derived from the individual to be treated (from their pre-natal s such as placenta, umbilical cord blood,
or umbilical cord matrix or expanded from the individual at any time after birth) (autologous). Or banks can
n cells for allogeneic uses. A master cell bank is a reservoir of cells to provide an aliquot of cells that
can be further expanded to provide doses for administration to a subject.
A cally-relevant” number of cells refers to a number of cells that is sufficient to effect a
clinical response; that is, a prevention, reduction, amelioration, etc. of an undesirable pathological condition
in a subject. A particular ment pertains to a number of cells that is ient to create a master cell
bank.
“Co-administer" means to administer in conjunction with one another, together, coordinately,
including simultaneous or sequential administration oftwo or more .
“Comprising” means, without other limitation, including the referent, necessarily, t any
qualification or exclusion on what else may be included. For example, “a composition comprising x and y”
encompasses any composition that ns x and y, no matter what other components may be present in the
ition. Likewise, “a method comprising the step of x" encompasses any method in which x is carried
out, whether it is the only step in the method or it is only one of the steps, no matter how many other steps
W0 2012/168295
there may be and no matter how simple or complex x is in comparison to them. “Comprised of and similar
phrases using words of the root “comprise” are used herein as synonyms of “comprising” and have the same
“Comprised of’ is a m of“comprising” (see .
“Conditioned cell culture medium” is a term well-known in the art. and refers to medium in which
cells have been grown. Herein this means that the cells are grown for a sufficient time to secrete the factors
that are effective to achieve any of the results described in this application.
Conditioned cell e medium refers to medium in which cells have been cultured so as to
secrete factors into the medium. For the purposes of the present invention, cells can be grown through a
sufficient number of cell divisions so as to produce ive amounts of such factors so that the medium has
the effects. Cells are removed from the medium by any of the known methods in the art, including, but not
limited to, centrifugation, filtration, immunodepletion (e.g., via tagged antibodies and magnetic columns),
and FACS sorting.
“EC cells” were discovered from is of a type of cancer called a teratocarcinoma. In 1964,
researchers noted that a single cell in teratocarcinomas could be isolated and remain undifferentiated in
e. This type of stem cell became known as an embryonic oma cell (EC cell).
“Effective amount” generally means an amount which provides the desired local or systemic effect.
For example, an effective amount is an amount sufficient to effectuate a beneficial or desired clinical result.
The effective amounts can be provided all at once in a single administration or in fractional s that
provide the effective amount in several administrations. The precise determination of what would be
considered an effective amount may be based on factors individual to each subject, including their size, age,
injury, and/or disease or injury being treated, and amount of time since the injury occurred or the disease
began. One skilled in the art will be able to determine the efl'ective amount for a given subject based on
these considerations which are e in the art. As used herein, “effective dose” means the same as
“effective amount.”
“Effective route” generally means a route which provides for delivery of an agent to a desired
compartment, system, or location. For example, an effective route is one through which an agent can be
administered to provide at the d site of action an amount of the agent sufficient to effectuate a
beneficial or desired clinical result.
“Embryonic Stem Cells (ESC)" are well knowu in the art and have been prepared from many
different mammalian s. Embryonic stem cells are stem cells d from the inner celi mass of an
early stage embryo known as a blastocyst. They are able to differentiate into all derivatives of the three
W0 2012/168295
primary germ layers: mi, endoderm, and mesoderm. These include each of the more than 220 cell
types in the adult body. The ES cells can become any tissue in the body, excluding placenta. Only the
morula’s cells are totipotent. able to become all tissues and a placenta. Some cells similar to ESCs may be
produced by nuclear transfer of a somatic cell nucleus into an enucleated fertilized egg.
“Expand” means to e a clinically-relevant number of cell ons of the output. cell.
“Clinically relevant" means that ent cell doublings of these cells are achieved in and/or on the fibers to
provide clinicallyaelevant numbers of the output cells. Hollow fiber bioreactor technology has been used
for es other than actual cell expanSion that produces clinically-relevant numbers of output cells. For
example, such bioreactors have been used to differentiate an input population of cells, to concentrate an
input population of cells, to treat blood and other fluids by means of an input population of cells, and the
like. In these embodiments, the cells associated with the fibers are not actually output cells. They are
adhered to the fibers, not so that they will expand, but for a different e. Nevertheless, in the
ames used to achieve these other purposes, some of the input cells may, in fact, expand. What
distinguishes this from the current ation of the technology is that the expansion of the cells is not
achieved in clinically-relevant numbers. Cell doubling is limited.
The term “hollow fiber" is intended to include hollow structures (of any shapclcontaining pores of
defined size, shape and y for use in delivering nutrients (in solution) to cells contained within a
bioreactor and for removal of waste materials (in solution) from cells contained within a biorcactor. For
purposes of the present invention, hollow fibers may be ucted of a resorbable or nonresorbable
material. Fibers include, but are not limited to, tubular ures.
Use ofthe term “includes” is not intended to be limiting.
“Increase“ or “increasing” means to induce entirely where there was no pre-existing presence or to
increase the degree of.
“Induced pluripotent stem cells (IPSC or IPS cells)” are somatic cells that have been
reprogrammed, for example, by introducing exogenous genes that confer on the c cell a less
differentiated ype. These cells can then be induced to differentiate into less differentiated progeny.
IPS cells have been derived using modifications of an approach originally discovered in 2006 (Yamanaka, S.
et al., Cell Stem Cell, 1:39—49 (2007)). For example, in one instance, to create IPS cells, scientists started
with skin cells that were then modified by a standard laboratory technique using retroviruses to insert genes
into the cellular DNA. In one instance, the inserted genes were Oet4, Son, Lif4, and c-myc, known to act
er as natural regulators to keep cells in an embryonic stem cell-like state. These cells have been
described in the ture. See, for example, Wernig et al., PNAS, 10525856-5861 (2008); Jaenisch et al.,
Cell, 1321567-582 (2008); Hanna et al., Cell, 133:250-264 (.2008); and Brambrink et al., Cell Stem Cell,
2:151-159 . These references are incorporated by nce for teaching IPSCs and methods for
producing them. It is also possible that such cells can be created by c culture conditions (exposure to
specific agents).
The “input cell population" refers to the cell type introduced into the biorcactor for expansion of
that cell type and that will tely form the output cell population. The input cell population can be
introduced into the bioreactor in very small numbers. For example, in bone marrow, the desired input cell
population may originally be found in cell numbers as low as one in a million. Alternatively, the input
population may be substantially homogeneous, such as derived from a cell bank and further ed in the
bioreactor.
The term “isolated” refers to a cell or cells which are not associated with one or more cells or one
or more cellular components that are associated with the cell or cells in viva. An “enriched tion”
means a relative increase in numbers of a desired cell relative to one or more other cell types in vivo or in
primary culture.
r, as used herein, the term “isolated” does not indicate the presence of only stem cells.
Rather, the term “isolated” indicates that the cells are removed from their natural tissue environment and are
present at a higher concentration as compared to the normal tissue nment. Accordingly, an “isolated”
cell population may further include cell types in on to stem cells and may include additional tissue
ents. This also can be expressed in terms of cell doublings, for example. A cell may have
undergone 10, 20, 30, 40 or more doublings in vitro or ex vivo so that it is enriched compared to its original
numbers in vivo or in its al tissue environment (e.g., bone marrow, peripheral blood, adipose tissue,
etc.).
[0093} “MAPC” is an acronym for “rnultipotent adult progenitor cell." It refers to a cell that is not an
embryonic stem cell or germ cell but has some characteristics of these. MAPC can be characterized in a
number of alternative ptions, each of which conferred novelty to the cells when they were discovered.
They can, therefore, be characterized by one or more of those descriptions. First, they have extended
replicative capacity in culture without being transformed (tumorigenic) and with a normal karyotype.
Second, they may give rise to cell progeny of more than one germ layer, such as two or all three germ layers
(i.e., endoderm, mesoderm and ectoderm) upon differentiation. Third, although they are not embryonic stem
cells or germ cells, they may express markers of these primitive cell types so that MAPCs may express one
or more of Oct. 3/4 (i.e., Oct 3A), rex-l, and rox-l. They may also express one or more of sox-Z and SSEA-
4. Fourth, like a stem cell, they may self-renew, that is, have an extended replication capacity without being
transformed. This means that these cells express telomerase (i.e., have telomerase activity). Accordingly,
the cell type that was designated “MAPC” may be characterized by ative basic characteristics that
describe the cell via some of its novel properties.
The term “adult” in MAPC is non-restrictive. It refers to a non-embryonic somatic cell. MAPCs
are karyotypically normal and do not form teratomas in viva. This acronym was first used in U.S. Patent No.
7,015,037 to describe a pluripotent cell isolated from bone marrow. However, cells with otential
markers and/or differentiation potential have been discovered subsequently and, for purposes of this
invention, may be equivalent to those cells first designated “MAPC.” ial descriptions of the MAPC
type of cell are provided in the Summary ofthe ion above.
MAPC represents a more primitive progenitor cell population than MSC (Verfaillie, C.M., Trends
Cell Biol 12:502—8 (2002), Jahagirdar, B.N., et al., Exp Hematol. 292543-56 (2001); Reyes, M. and CM.
Verfaillie, Arm N YAcad Sci, 938:231-233 (2001); Jiang, Y, et 211., Exp Hematol, 30896-904 (2002); and
(Jiang, Y. et al., Nature, 418241-9. (2002)).
The term “MultiStern®” is the trade name for a cell preparation based on the MAPCs of U.S. Patent
No. 7,015,037, i.e., a non-embryonic stem, non-germ cell as described above. MultiStem® is prepared
according to cell culture methods disclosed in this patent application, particularly, lower oxygen and higher
serum. tem® is highly expandable, karyotypically normal, and does not form teratomas in viva. It
may differentiate into cell lineages ofmore than one germ layer and may express one or more of telomerase,
, rex-l, rox-l, sex-2, and SSEA4.
The term “nutrient solution” is intended to include solutions entering a bioreactor and containing
those- nutrient als essential to the culture ofmammalian or vertebrate cells. Nutrient solutions may also
contain additives that affect specific changes in phenotype of cells under culture or to contribute to changes
in the matrix ure of the forming newly formed bone, such as, mineralization.
Nutrients are delivered to the cells in the bioreactor and may impact the growth and differentiation
of cells contained in the bioreactor. The nutrient solutions are selected to provide ent nutrition to the
cells to maintain viability, growth, and/or entiation in the bioreactor. Those skilled in the art are
capable of selecting an appropriate nutrient solution for the present invention. For e, media such as
Dulbecco's modified Eagle's medium may be used and may be further mented with other suitable
nutrients. Other suitable nts include fetal bovine serum, L-ascorbic acid,phosphate, antibiotics, cell
modulators such as dexamethasone, beta—glycerolphosphate, glucose, glutamine, amino acid supplements,
inhibitors (or activators) of apoptosis such as glutathione-ethyl ester, antioxidants, caspase inhibitors, and
cations and anions, e.g., magnesium, ese, calcium, ate, chloride, sodium, potassium, zinc, and
sulfate ions, and es and nitrites. The ing concentration of components in the nutrient solution
should be sufficient to promote growth in the bioreactor and maintain viability of the cells.
The “output cell population” refers to the cells that one desires to harvest from the bioreactor after
having been expanded in the bioreactor. Harvested cells are defined as those that are removed from the
bioreactor that will then be used in the clinic or for other purposes, for example, research, al trials, and
the like.
] “Primordial embryonic germ cells” (PG or E0 cells) can be cultured and stimulated to produce
many less differentiated cell types.
“Progenitor cells” are cells produced during differentiation of a stem cell that have some, but not
all, of the characteristics of their nominally-differentiated progeny. Defined progenitor cells, such as
“cardiac progenitor cells,” are ted to a lineage, but not to a c or terminally differentiated cell
type. The term “progenitor” as used in the acronym “MAPC” does not limit these cells to a particular
lineage. A progenitor cell can form a y cell that is more highly differentiated than the itor cell.
Selection could be from cells in a tissue. For example, in this case, cells would be isolated from a
desired tissue, expanded in culture, selected for a desired characteristic, and the selected cells further
expanded.
“Self-renewal” refers to the ability to produce replicate daughter stem cells having differentiation
potential that is identical to those from which they arose. A similar term used in this context is
“proliferation.”
“Serum—free ” refers to medium in which serum is not t or, if present, is at levels at
which the components of the serum have no effect on the growth or variability of the cells (i.e., are not
actually necessary, such as residual or trace amounts).
“Stem cell” means a cell that can undergo self-renewal (i.e., progeny with the same differentiation
potential) and also e progeny cells that are more restricted in differentiation potential. Within the
context of the invention, a stem cell would also encompass a more differentiated cell that has den
differentiated, for example, by nuclear transfer, by fusion with a more primitive stem cell, by introduction of
specific transcription factors, or by culture under specific conditions. See, for example, Wilmut et al.,
Nature, 0-813 ; Ying et al., Nature, 416:545-548 (2002); Guan et a1., Nature, 440:1199-1203
(2006); Takahashi ct a1., Cell, 3-676 (2006); Okita et al., Nature, 448:313-317 (2007); and Takahashi
et a1., Cell, 131:861-872 (2007).
Dedifferentiation may also be caused by the administration of certain compounds or exposure to a
physical environment in vitro or in vivo that would cause the dedifferentiation. Stem cells also may be
derived from abnormal tissue, such as a teratocarcinoma and some other sources such as id bodies
(although these can be considered embryonic stem cells in that they are derived from embryonic tissue,
although not directly from the inner cell mass). Stem cells may also be produced by ucing genes
ated with stem cell ftmction into a non-stem cell, such as an induced pluripotent stem cell.
“Subject” means a vertebrate, such as a mammal, such as a human. Mammals include, but are not
limited to, humans, dogs, cats, horses, cows, and pigs.
] The term “waste solution” is ed to include solutions exiting a bioreactor and containing
waste byproducts of cellular metabolism. The concentrations of waste byproducts, for example ammonia,
lactic acid, etc. and al levels of nutrients such as glucose, in the waste solution can be used to assess
the levels of metabolic activity of cells being cultured in a bicreactor.
Bioreactors
Bioreactors, especially bioreactors used for tissue regeneration processes, are well known. See, for
example, US. 169; 6,197,575; 6,080,581; 5,677,355; 5,433,909; 5,898,040, incorporated by reference.
A ctor is a generalized term that ially covers any kind of vessel that is capable of
incubating cells while providing a degree of protection for the cells' environment. A bioreactor may be a
static vessel such as a flask or culture bag in which the variables (such as composition of growth media,
hand
oxygen tration, pH levels, and osmolarity) are not fully controlled and monitored. On the other
there are fully automated electromechanical of-the-art bioreactors in which all the variables are
monitored and controllable. Many inter-combinations between these examples are well known to one of
ordinary skill in cellular biotechnology.
Three different traditional ches for the cultivation of isolated hematopoietic stem or
progenitor cells have been described in the ture: the , the stirred and the immobilized culture.
Static ation takes place in very simple culture systems such well plates, tissue-culture flasks or gas-
permeable culture bags. As the former two systems do not allow cell cultivation on a clinical scale, the latter
is actually the most-often used technique for stem cell expanSion (Purdy et al., J Hematother, 4:515-525
(1995); McNiece et al., Hematol Cell Ther, 4:82-86 (1999); and McNiece et 211., Exp Hematol, 28:1181-1186
(2000a)). All these systems have the advantage of being easy to handle, single-use devices, which enable an
uncomplicated cell harvest. However, with all these systems, process control modulation is efi'ected via
control of the incubator nment, and there is no provision of continuous feeding. Thus, variations in
culture conditions during cultivation (e.g., oxygen tension, pH, substrate, metabolite and cytokine
concentrations) are critical factors in all three methods of static cultivation.
Stirred bioreactors are cormnonly used in animal cell culture, offering a homogenous
nment, representative sampling, better access to process control and an increased oxygen transfer.
Several of stirred techniques (spinner flasks and stirred vessel bioreactors) have been 'successfiilly
implemented in the cultivation of poietic cells tra et al., BiotechnOI, 12:909—914 (1994)).
The immobilization of stem and progenitor cells is an attempt to reach local high cell ies and
to e the three-dimensional structure of the tissue (such as bone marrow) without the use of stromal
feeder layer. In immobilized biocatalyst reactors, the cells may be immobilized in or on a can-ier,
immobilized by linkage among one another to form larger particles or confined within membrane barriers.
Most of the reactors can be run in a batch, fed-batch or continuous mode. Immobilized bioreactors are well
known in the art, such as the conventional rs such as Continuous Stirred Tank Reactors (CSTR) and
Packed Bed rs (PBR) as described in standard text books such as Ullmann's Encyclopedia Of
hidusu'ial Chemistry: Fifth edition, T. Campbell, R. Pfeflerkom and J, F. Rounsaville Eds, VCH Publishers
1985, Vol A4, pp 141-170; Ullmann's Encyclopedia Of Industrial Chemistry: Fifth ed., B. Elvers, S.
Hawkins and G. Schulz Eds, VCH Publishers, 1992, Vol B4, pp 381-433; J. B. Butt "Reaction Kinetics And
r Design" Prentice-Hall, Inc., 1980, pp 1.
] Thus, bioreactors can be grouped according to general categories including: static bioreactors,
stirred flask bioreactors, rotating wall vessel bioreactors, hollow fiber bioreactors and direct perfusion
bioreactors. Within the bioreactors, cells can be free, or immobilized, seeded on porous 3-dimensional
scaffolds (hydrogel).
Hollow fiber bioreactors can be used to enhance the mass transfer during culture. Thus, for the
have the stem
present invention, the bioreactor is a hollow fiber bioreactor. Hollow fiber bioreactors may
and/or progenitor cells embedded within the lumen of the fibers, with the medium perfusing the extra—
l space or, atively, may provide gas and medium ion through the hollow fibers, with the
cells growing within the extralumenal space. Such hollow fiber bioreactors suitable for the present ion
have been disclosed as described herein, and some are commercially available, such as the Caridian
(Terumo) BCT Quantum Cell Expansion System.
A ctor is defined as any device that provides the physiological requirements of the cell (for
example, pH. ature, pressure, nutrients, supply and waste removal) for the standard production of
cells and their products. A bioreactor can enhance mass transport in engineering ctors for cell
proliferation. There is continuous nutrition of cells and removal of waste products. For autologous
administration of cells, a bioreactor should be vely compact, disposable, and economical. Generally, a
large chamber/volume ratio is required. Finally, to keep cells in a specific entiation state may require
growth factors or serum components and, thus, a bearing bioreactor is desirable. These requirements
are met by the hollow fiber bioreactor-based cell expansion system described in er et
In the apparatus described in Antwiler et al., the system provides a chamber growth volume of
around 120 ml although larger chamber volumes can be accommodated. For growth, a surface area of 1.7 m2
is provided. Thus, both adherent and suspension cells can be grown in this device, including co-cultures. The
other physical characteristics are length, 295 mm; inner diameter, 215 pm; IC volume, 104 ml; EC volume,
W0 2012/168295
330 ml; number of fibers, 9000. Fibronectin may be used as a coating for adherent cells. The device can
maintain all required experimental conditions for growing a cell of st, such as gas concentration, pH,
media, temperature, management of nutrients, waste products, and ed additives. To t
contamination, the system is ed with a closed sterile fluid compartment. Bags of media reagents and
solutions remain attached to the system so that feeding schedules, waste removal, and general cell e
nment can be replaced, controlled, and optimized as d. The unit can be used on the bench top.
Cells can be grown inside Outta-capillary), outside (extra-capillary), or simultaneously on both sides of the
fibers. This hollow fiber bioreactor design allows for direct connection using tubing which can be routed
through appropriate peristaltic pumps, pinch valveS, etc, to obtain a closed system. Gas control is managed
using a hollow fiber oxygenaror. The system also odates the ability to add and harvest cells, replace
medium, and add reagents, etc. Thus, bags are used for all fluids and the bag connections all use sterile
connecting technology. Schematic representation is found in Fig, 4.
In the exemplified embodiment in this application (Example 1) the continuous flow bioreactor has
an internal fluid volume of 184 ml and an external fluid volume of 303 ml containing 1.1 x 104 hollow fibers
with a total surface area (intra—capillary) of approximately 2.1 m2 (3255 inz), a wall ess of 50 um,
diameter of 215 um, and length of295 mm. Pore size has a 16 kDa cutoff for passage of components.
The hollow fibers should be suitable for the ry of nutrients and removal of waste in the
bioreactor. The hollow fibers may be any shape, for e, they may be round and tubular or in the form
of concentric rings, The hollow fibers may be made up of a resorbable or non-resorbable membrane. For
example, suitable components of the hollow fibers include polydioxanone, polylactide, actin,
ycolic acid, polylactic acid, polyglycolic acid/trimethylene carbonate, cellulose. methylcellulose,
cellulosic polymers, cellulose ester, regenerated cellulose, pluronic, collagen, elastin, and mixtures thereof.
The large variety of suitable materials is well-known in the art and is represented by a large body of
literature. Examples of these materials have been described in US. Patents 4,220,725; 4,184,922:
4,200,689; 3,821,087; 3,883,393; 4,184,922; 4,200,689; 396; 4,220,725; 4,999,298; 4,804,628;
,126,238; 5,656,421; 5,162,225; 5,622,857; 5,627,070; 585; 6,911,201; 6,933,144; 609; and
US. Publications 2007/0298497; 2008/0220523; 2001/0044413; 2009/0196901; 2010/0233130;
2009/0191631; 2005/0032218; 2005/0003530; 2003/0224510; 2006/0205071; 2010/0267134;
2008/0206733; 209403, 2008/0213894; 2008/0220522; 227190; 2008/0248572;
2008/0254533; 2010/0144037; and 2010/0042260 all of which are incorporated by reference for teaching
these materials. The criteria for wall materials includes, but is not limited to, the following: not toxic to the
cells; porous for the removal of waste and the reception of nutrients and, in instances where collection of
components secreted by the cell is desired, porosity is adjusted for that parameter; relatively insensitive to
temperature changes, i.e, thermally stable; able to retain shape integrity.
It is also known that such materials are impermeable to cells but ble to a variety of d
materials. Thus, the hollow fibers include pores to allow the nutrients and waste to pass in and out of it. The
allow the diffusion of a molecule from one side of the
pores of the hollow fibers are a sufficient diameter to
hollow fiber to the other side of the hollow fiber. ably, the molecules that may pass through the hollow
fiber pores are about 0.002 to about 50 kDa, more preferably about 5 to about 25 kDa, or most preferably
about 2 to about 16 kDa. Accordingly, the pore size of the fiber walls can be varied depending on the
components that one desires to pass through the walls. For example, pore size can allow Only small
molecules or, maybe, larger to allow the passage of large proteinacious molecules, including growth factors,
including, but not limited to, epidermal growth factor and platelet—derived growth factor. The person of
ordinary skill in the art would understand how to vary the pore size depending upon the components that it is
desirable to pass through the fiber walls to reach the cells or to carry material from the cells. For example, it
cells for further use. The cells, for example,
may be desirable to collect components that are made by the
and other components that
may express and secrete cytokines, growth factors, immunomodulatory factors,
are further useful. Materials that may be carried from the cells also include waste products that one desires
to remove from the cell. Accordingly, this technology could be used to produce medium conditioned by the
cells ning useful components.
A number of bioreactor configurations exist for culturing age-dependent cells, such as
those of the invention. But this invention is not ent on any particular configuration. One example is
ed in US. Publication No. 2007/0298497, which discloses a configuration that has been used to grow
mesenchymal stem cells.
One example, in US. 2007/0298497 (not meant to be limiting), is a hollow fiber bioreactor shown
in Figure 2. A cell ion module or bioresctor 10 which may be used in the present invention is made of
a bundle of hollow fiber membranes 12 enclosed within a housing 14. The bundle of hollow fibers is
tively referred to as a ne. The g or module 14 may be cylindrical in shape and may be
made of any type of biocompatible polymeric material.
Each end of the module 14 is closed off with end caps or headers 16, 18. The end caps 16, 18 may
be made of any suitable material such as polycarbonate so long as the material is biocompatible with the
cells to be grown in the bioreactor.
There may be at least four ports into and out of the module. Two ports fluidly connect to the
extracapillary into the
space (EC space), one port 34 for fresh extracapillary media ingress space
surrounding the hollow fibers and one port 44 for spent extracapillary media egress out of the module. Two
for fresh intraeapillary media
ports also fluidly comiect to the intracapillary space (1C space), one port 26
ingress into the lumen of the hollow fibers as well as for the introduction of the cells to be expanded, and
from the bioreactor.
one port 42 for spent apillary media egress and l of expanded cells
Cells to be expanded in the bioreactor may be flowed into the 1C space or the EC space. The
bioreactor may be loaded with cells using a syringe or the cells may be distributed into the IC or EC spaces
directly from a cell separator. The cells may also be introduced into the growth module or bioreactor from a
cell input bag or flask (shown as element 5) which may be sterile docked to the bioreactor.
In one embodiment, the hollow fiber wall material that can be used includes, but is not d to,
two types, a 0.5% thermoplastic polyurethane sold under the trade name Desmopan.RTM. (available from
Bayer MaterialScienee AG, DE) and Polyflux.RTM., which is a trade name for a dialyzer with a membrane
of Polyamjx.RTM (a blend of polyamide, polyarylethersulfone and polyvinylpyrrolidone) (available from
Gambro Dialysatoren, GmBH, Hechingen, Del.) ( Hoenich, et a1. (2000) ASAIO 1., 4627075, incorporated
by reference).
] US. 2008/0220523 provides a cell expansion system and methods for using it that, in a specific
embodiment, are suitable to grow the cells described herein. The cell expansion system generally includes a
hollow fiber cell growth chamber and first and second circulation loops (intra-capillary loops and extra-
capillary loops) ated with the interior of the hollow fibers and exterior of the hollow fibers,
respectively. Detachable flow ts and s of expanding cells are also provided. The cell growth
chamber is described below and also is shown in Figure 3.
Cell Growth Chamber (US. 2008/0220523']
The cell growth chamber ofthe cell expansion system generally includes a hollow fiber membrane
comprised of a plurality of semi-permeable hollow fibers ting first and second fluid circulation paths.
An exemplary cell growth chamber is depicted in Figure 3, which depicts a ay side view of
the hollow fiber cell growth chamber 200. Cell growth chamber 200 is bounded by cell growth chamber
housing 202. Cell growth r g 202 further es four gs, or ports: inlet port 204, outlet
port 206, inlet port 208, and outlet port. 210.
Fluid in the first circulation path enters cell growth r 200 through inlet port 204, passes
into and through the intracapillary side of a plurality of hollow fibers (referred to in various embodiments as
the intracapillary (“1C”) side or “IC Space” of a hollow fiber membrane), and out of cell growth chamber
200 through outlet port 206. The terms “hollow fiber," “hollow fiber capillary,” and “capillary” are used
interchangeably. A plurality of hollow fibers is collectively referred to as a “membrane." Fluid in the
second ation path flows in the cell growth chamber through inlet port 208, comes in contact with the
outside of the hollow fibers (referred to as the “EC side” or “EC space” of the membrane), and exits cell
growth chamber 200 via outlet port 210. Cells can be contained within the first circulation path or second
circulation path, and can be on either the 1C side or EC side of the membrane.
W0 2012/]68295
] Although cell growth chamber housing 202 is depicted as cylindrical in shape, it can have any
other shape known in the art. Cell growth chamber housing 202 can be made of any type of biocompatible
polymeric material. Various other cell grth chamber housings may differ in shape and size.
Those of skill in the art will recognize that the term “cell growth chamber” does not imply that all
cells being grown or ed in a cell expansion system are grown in the cell growth chamber. nt
cells can adhere to membranes disposed in the growth chamber, or may grow within the associated tubing.
Non-adherent cells (also referred to as “suspension cells”) can also be grown. Cells can be grown in other
areas within the first. or second fluid circulation path.
For example, the ends of hollow fibers 212 can be potted to the sides of the cell growth chamber
by a connective material (also referred to herein as “potting” or “potting material”). The potting can be any
suitable material for binding the hollow fibers 212, provided that the flow of media and cells into the hollow
fibers is not obstructed and that liquid flowing into the cell growth chamber through the IC inlet port flows
only into the hollow fibers. Exemplary potting materials include, but are not limited to, polyurethane or
other suitable binding or adhesive components. In s embodiments, the hollow fibers and potting may
be cut through perpendicular to the central axis of the hollow fibers at each end to permit fluid flow into and
out of the IC side. End caps 214 and 216 are disposed at the end of the cell growth chamber.
Fluid entering cell growth r 200 via inlet port 208 is in contact with the outside of hollow
fibers. This portion of the hollow fiber cell growth chamber is referred to as the “extracapillary (EC) ”
Small molecules (e.g. water, oxygen, lactate, etc.) can diffuse through the hollow fibers from the or of
the hollow fiber to the EC space, or from the EC space to the IC space. Large lar weight molecules
of the hollow fibers. The
are typically too large to pass through the hollow fibers, and remain in the 1C space
media may be replaced as needed Media may also be circulated through an ator to exchange gasses
as needed.
In s embodiments, cells can be loaded into the hollow fibers by any of a variety of methods,
including by syringe. The cells may also be introduced into the cell growth chamber from a fluid container,
such as a bag, which may be fluidly associated with the cell growth r.
Hollow fibers are configured to allow cells to grow in the intracapillary space (i.e. inside the
hollow fiber lumen) of the fibers. Hollow fibers are large enough to allow cell adhesion in the lumen without
substantially impeding the flow of media through the hollow fiber lumen. In various ments, the inner
diameter of the hollow fiber can be greater than or equal to 10000, 9000, 8000, 7000, 6000, 5000, 4000,
3000, 2000. 1000, 900, 800, 700, 650, 600, 550, 500, 450, 400, 350, 300, 250, 200, 150, or 100 microns.
Likewise, the outer diameter of the hollow fiber can be less than or equal to 10000, 9000, 8000, 7000, 6000,
W0 2012/168295
5000, 4000, 3000, 2000, 1000, 900, 800, 700, 650, 700, 650, 600, 550, 500, 450, 400, 350, 300, 250, 200,
150, or 100 microns. The hollow fiber wall thickness is sufficient to allow diffusion of small molecules.
Any number ofhollow fibers can be used in a cell growth chamber, provided the hollow fibers can
be fluidly associated with the inlet and outlet ports of the cell growth chamber. In various embodiments, the
cell growth chamber can e a number of hollow fibers greater than or equal to 1000, 2000, 3000, 4000,
5000, 6000, 7000, 8000, 9000, 10000, 11000 or 12000. In other embodiments, the cell growth chamber can
include a number of hollow fibers less than or equal to 12000, 11000, 10000, 9000, 8000, 7000, 6000, 5000,
4000. 3000, or 2000. in other various embodiments, the length of the hollow fibers can be r than or
equal to 100, 200, 300, 400, 500, 600, 700, 800, or 900 millimeters. In certain embodiments, the cell growth
chamber contains approximately 9000 hollow fibers that. have an average length of 295 mm, an average
inner diameter of 215 microns, and an average outer diameter of 315 microns.
Hollow fibers can be constructed of any material capable of forming a size sufficient to form
fibers capable of transporting liquid from the cell growth chamber inlet port to the cell growth chamber
outlet port. In various embodiments, the hollow fibers can be constructed from plastic adherent materials
capable of binding to certain types of cells, such as adherent stem cells. In various other embodiments,
hollow fibers can be treated with compounds such as fibroncctin to form adherent surfaces.
In certain embodiments, the hollow fibers may be made of a send-permeable, biocompatible
polymeric material. One such polymeric al which can be used is a blend of polyamide,
polyarylethersulfone and nylpyrrolidone ("PA/PAES/PVP"). The semi—permeable membrane allows
er of nutrients, waste and dissolved gases through the membrane between the EC space and IC space.
In s embodiments, the molecular transfer teristics of the hollow fiber membranes are chosen to
minimize loss of expensive reagents necessary for cell growth such as growth factors, cytokines etc. from
the hollow fiber, while ng metabolic waste products to e through the membrane into the hollow
fiber lumen side to be d.
In certain variations, one outer layer of each PA/PAES/PVP hollow fiber is characterized by a
homogenous and open pore structure with a defined e roughness. The openings of the pores are in the
size range of 0.5-3 um, and the number of pores on the outer surface of the fibers are in the range of 10,000
to 150,000 pores per m2, This outer layer has a thickness of about 1 to 10 um. The next layer in each
hollow fiber is a second layer having the form of a sponge structure and, in a timber ment, a
thiclcness of about 1 to 15 pm. This second layer serves as a t for the outer layer. A third layer next to
the second layer has the form of finger~like structures. This third layer provides mechanical stability and a
high void volume which gives the membrane a very low resistance to transporting molecules through the
membrane. During use, the fingenlike voids are filled with fluid and the fluid gives a IOWer resistance for
PCT/EP2012l060690
ion and convection than a matrix with a sponge—filled structure having a lower void volume. This third
layer has a thickness of 20 to 60 pm
In further ments, the hollow fiber membrane can include 65-95% by weight of at least one
hydrophobic polymer and 5-35% by weight of at least one hydrophilic r. The hydrophobic polymer
may be chosen from the group consisting of polyamide (PA), polyaramide (PAA), polyarylethersulphone
(PAES), polyethersulphone (PES), polysulphone (PSU), polyarylsulphone (PASU), rbonate (PC),
polyether, polyurethane (FUR), polyetherimide and copolymer mixtures of any of the above polymers, such
as polyethersulphone or a mix of polyarylethersulphone and polyamide. In additional embodiments, the
philic polymer may be chosen from the group consisting of polyvinylpyrrolidone (PVP), polyethylene
glycol (PEG), ycolmonoester, water soluble cellulosic derivates, polysorbate and polyethylene-
polypropylene oxide copolymers.
Depending upon the type of cells to be expanded in the cell growth chamber, the polymeric fibers
may be treated with a substance, such as fibronectin, to enhance cell growth and/or adherence of the cells to
the membrane.
US. 2008/0220523 and US. 2008/0248572 also have examples of other detailed reactor
ments, including ed flow chart protocols. These various embodiments can be found, for
e, in Figures 1B, 1C, and ID of U.S. 2008/0220523. The flow chart protocols pertain to Figure 1D.
Any of these would be le for cing the invention. See also the embodiments disclosed in US.
2008/0220522. All this text is incorporated by reference for disclosing these embodiments for use with the
cells according to the present invention.
WO/2010/034468 provides another exemplary device comprising two compartments separated by
a semi-permeable membrane mounted in a casing, a first internal compartment fitted with two accesses and a
second al compartment comprising one or two accesses, both compartments being also ted by a
potting compound, based on an appropriate adhesive nd, intended for forming as applicable (i) a
cylindrical partition separating both compartments of said device ning a semi-permeable membrane of
the hollow fiber bundle type as defined above or (ii) a tight seal in said device including a semi-permeable
membrane of the sheet membrane type as defined above .
Another exemplary device comprises a plurality of hollow fiber membranes, contained within an
outer shell, and configured so that fluid within a space external to the hollow fibers (i.e., an extracapillary
compartment) is segregated from fluid passing through the hollow fibers and their corresponding orifices.
Additionally, the device includes two manifold end chambers within the outer shell on opp0site ends of the
device. Each of the two orifices of a hollow fiber connects to a different end chamber. The end chambers
and the extracapillary compartment are separated by the ermeable membranes of the hollow fibers.
The composition within the extracapillary compartment can be controlled, to a certain extent, by the
molecular weight cutoff, or pore size, of the membranes of the hollow fibers.
] In one mode of operating the device, cells are grown in the extracapillary compartment while a
nutrient medium is passed through the hollow fibers. In another mode of operating the device, cells are
grown in the intracapillary space (Le. lumen) of the hollow fibers while a nutrient medium is passed through
the apillary compartment and/or the intracapillary compartment. The semi—permeable nature of the
hollow fibers allows nutrients and cell waste products to pass through the walls of the hollow fibers while
blocking cells from doing the same.
Shell-and-tube type bioreactors provide several advantages. For adherent cells, the use of several
hollow fibers provides, within a vely small volume, a large amount of surface area upon which the cells
can grow. This large amount of surface area also facilitates localized distribution of nutrient media to the
g cells and ready collection of cell waste products. Shell-and-tube type bioreactors enable the growth
of cells at much higher density than is possible with other cell culture devices. They can support cell
densities greater than 108 cells per milliliter, whereas other cell culture devices are typically limited to
densities around 106 cells per milliliter.
Stem Cells
] The present invention can be practiced, preferably, using stem cells of vertebrate species, such as
humans, non-human primates, domestic animals, livestock, and other non-human mammals. These include,
but are not d to, those cells described below.
Embryonic Stem Cells
The most well studied stem cell is the embryonic stem cell (ESC) as it has unlimited self-renewal
and multipotent differentiation potential. These cells are d from the inner cell mass of the blastocyst
or can be derived from the primordial germ cells of a mplantation embryo (embryonal germ cells or
EG cells). ES and EG cells have been derived, first from mouse, and later, from many ent animals, and
more recently, also from man primates and humans. When introduced into mouse blastocysts or
blastocysts of other animals, ESCs can contribute to all tissues of the animal. ES and EG cells can be
identified by positive staining with antibodies against SSEAl (mouse) and SSEA4 (human). See, for
example, US. Patent Nos. 5,453,357; 5,656,479; 5,670,372; 5,843,780; 301; 5,914,268; 6,110,739
6,190,910; 6,200,806; 6,432,711; 6,436,701, 6,500,668; 6,703,279; 6,875,607; 913; 7,112,437;
7,145,057; 7,153,684; and 7,294,508, each of which is orated by reference for teaching embryonic
W0 2012/168295
stem cells and methods of making and expanding them. Accordingly, ESCs and methods for isolating and
expanding them are well-known in the art.
A number of ription factors and exogenous cytokines have been identified that influence the
potency status ofembryonic stem cells in vivo. The first transcription factor to be described that is involved
in stem cell pluripotency is Oct4. Oct4 s to the POU (Pit~0ct-Unc) family oftranscription factors and
is a DNA binding protein that is able to activate the transcription of genes, containing an octameric sequence
called “the octamer motif" within the promoter or enhancer . Oct4 is expressed at the moment of the
cleavage stage of the fertilized zygote until the egg cylinder is formed. The on of 0ct3/4 is to repress
differentiation inducing genes (i.e., Foan3, hCG) and to activate genes promoting pluripotcncy (FGF4,
Utf‘l, Rexl). Sox2, a member of the high mobility group (HMG) box transcription factors, cooperates with
Oct4 to activate transcription of genes expressed in the inner cell mass. It is essential that 0ct3/4 expression
in embryonic stem cells is maintained between certain levels. Overexpression or downregulation of >50%
of Oct4 expression level will alter embryonic stem cell fate, with the formation of primitive
rm/mesuderm or trophectoderm, respectively. In vivo, Oct4 deficient embryos develop to the
blastocyst stage, but the inner cell mass cells are not pluripotent. Instead they differentiate along the
mbryonic trophoblast lineage. Sall4, a mammalian Spalt transcription factor, is an upstream regulator
of Oct4, and is therefore important to maintain appropriate levels of Oct4 during early phases of
embryology. When Sall4 levels fall below a certain threshold, trophectodermal cells will expand cally
into the inner cell mass. Another transcription factor required for pluripotency is Nanog, named after a
celtic tribe “Tir Nan 0g”: the land of the ever young. In vivo, Nanog is sed fiom the stage of the
compacted morula, is uently defined to the inner cell mass, and is down—regulated by the implantation
stage. gulation of Nanog may be important to avoid an uncontrolled expansion of pluripotent cells
and to allow multilineage differentiation during gastrulation. Nanog null s, ed at day 5.5,
consist of a disorganized blastocyst, mainly containing extraembryonic endoderm and no discemable
Non-Embmnic Stem Cells
Stem cells have been identified in most tissues. Perhaps the best characterized is the
hematopoietic stem cell (HSC). HSCs are mesoderm-derived cells that can be purified using cell surface
s and functional characteristics. They have been isolated from bone marrow, peripheral blood, cord
blood, fetal liver, and yolk sac. They initiate hematopoiesis and generate multiple hematopoietic lineages.
When transplanted into lethally-irradiated animals, they can repopulate the erythroid neutrophil-macrophage,
megakaryocyte, and id hematopoietic cell pool. They can also be induced to undergo some self-
renewal cell on. See, for example, US. Patent Nos. 5,635,387; 5,460,964; 5,677,136; 5,750,397;
,681,599; and 5,716,827. US. Patent No. 5,192,553 reports methods for isolating human neonatal or fetal
W0 2012/168295 2012/060690
hematopoietic stem or progenitor cells. U.S. Patent No. 5,716,827 reports human hematopoietic cells that
are Thy—l+ progenitors, and riate growth media to rate them in vitro. U.S. Patent No.
U.S.
,635,387 reports a method and device for culturing human poietic cells and their precursors,
Patent No. 6,015,554 describes a method of reconstituting human lymphoid and dendritic cells.
Accordingly, HSCs and methods for isolating and expanding them are well-known in the art.
Another stem cell that is well-known in the art is the neural stem cell (NSC). These cells can
neural
proliferate in vivo and continuously regenerate at least some neuronal cells. When cultured ex vivo,
ofneurons and glial cells.
stem cells can be induced to erate as well as entiate into different types
When transplanted into the brain, neural stem cells can engraft and generate neural and glial cells. See, for
example, Gage F.H., Science, 287:1433-1438 (2000), Svendsen SN. et a1, Brain Pathology, 9:499-513
(1999), and Okabe S. et 31., Mech Development, 59289402 . U.S. 5,851,832 reports otent
neural stem cells obtained from brain tissue. U.S. 5,766,948 reports producing neuroblasts from newborn
cerebral hemispheres. U.S. 5,564,183 and 5,849,553 report the use of mammalian neural crest stem cells.
U.S. 6,040,180 reports in vitro tion of entiated neurons from cultures of mammalian
multipotential CNS isolation of
stem cells. WO 98/50526 and WO 99/01159 report generation and
neuroepithelial stem cells, oligodendrocyte-astrocyte precursors, and lineage-restricted neuronal precursors.
U.S. 5,968,829 reports neural stem cells obtained from embryonic forebrain. Accordingly, neural stem cells
and methods for making and expanding them are well—known in the art.
Another stem cell that has been studied extensively in the art is the mesenchymal stem cell
(MSG). MSCs are d from the embryonal mesoderm and can be isolated from many sources, including
adult bone marrow, peripheral blood, fat, placenta, and umbilical blood, among others. MSCs can
differentiate into many mesodermal tissues, including muscle, bone, cartilage, fat, and tendon.
There is
considerable literature on these cells. See, for example, U.S. 5,486,389; 5,827,735; 5,811,094; 5,736,396;
539; 5,837,670; and 5,827,740. See also Pittenger, M. et al, e, 284:143-147 (1999).
Another example of an adult stern cell is adipose—derived adult stem cells (ADSCs) which have
been isolated from fat, typically by liposuction followed by release of the ADSCs using collagenase.
ADSCs are similar in many ways to MSCs derived from bone marrow, except that it is possible to isolate
many more cells from fat. These cells have been reported to differentiate into bone, fat, muscle, cartilage,
and neurons. A method of isolation has been described in U.S. 2005/0153442.
Other stem cells that are known in the art include gastrointestinal stem cells, epidermal stem cells,
Lond B Biol
and hepatic stem cells, which have also been termed “oval cells” (Potten, C., et al._, Trans R Soc
Sci, 353:821-830 (1998), Watt, F., Trans R Soc Lond B Biol Sci, 3531831 (1997); Alison et. al., logy,
292678—683 (1998).
Other non-embryonic cells reported to be capable of differentiating into cell types of more than
one embryonic germ layer include, but are not limited to, cells from umbilical cord blood (see U.S.
Publication No. 2002/0164794), ta (see U.S. Publication No. 2003/0181269, umbilical cord matrix
(Mitchell, ICE. et al., Stem Cells, 21:50-60 (2003)), small embryonic-like stem cells (Kucia, M. et al., J
Physiol Pharmacol, 57 Suppl 5:5-18 (2006)), amniotic fluid stem cells (Atala, A., J Tissue Regen Med, 1:83-
96 ), skin-derived precursors (Toma et al., Nat Cell Biol, 3:778—784 (2001)), and bone marrow (see
U.S. Publication Nos. 2003/0059414 and 2006/0147246), each of which is incorporated by reference for
teaching these cells.
Strategies of Reproggmming Somatic Cells
l different strategies such as nuclear transplantation, cellular fusion. and culture induced
reprogramming have been employed to induce the conversion of differentiated cells into an embryonic state.
Nuclear transfer involves the ion of a somatic nucleus into an ated oocyte, which, upon transfer
into a surrogate mother, can give rise to a clone (“reproductive cloning"), or, upon explantation in culture,
can give rise to genetically matched embryonic stem (ES) cells (“somatic cell nuclear transfer,” SCNT).
Cell fusion of somatic cells with ES cells results in the tion of hybrids that. show all features of
pluripotent ES cells. Explantation of somatic cells in culture s for immortal cell lines that may be
pluripotent or multipotent. At t, spermatogonial stem cells are the only source of pluripotent cells that
can be derived from postnatal animals. Transduction of somatic cells with defined factors can initiate
reprogramming to a otent state. These experimental approaches have been extensively reviewed
(Hochedlinger and Jaenisch, , 441:1061-1067 (2006) and Yamanaka, 8., Cell Stem Cell, 1:39-49
(2007)).
Nuclear Transfer
Nuclear transplantation (NT), also referred to as somatic cell nuclear transfer (SCNT), denotes the
introduction of a nucleus from a donor c cell into an enucleated ogocyte to generate a cloned animal
such as Dolly the sheep (Wilmut et 31., Nature, 385:810-813 (1997). The generation of live animals by NT
trated that the epigenetic state of somatic cells, including that of terminally differentiated cells, while
stable, is not irreversible fixed but can be reprogrammed to an embryonic state that is capable of directing
development of a new sm. In addition to providing an ng experimental approach for elucidating
the basic epigenetic mechanisms involved in nic development and disease, r cloning
technology is of potential interest for patient-specific transplantation ne.
Fusion of omatic Cells and Emb nic tem Cells
Epigenetic reprogramming of somatic nuclei to an undifferentiated state has been demonstrated in
murine hybrids produced by fusion of embryonic cells with somatic cells. Hybrids between various somatic
cells and embryonic carcinoma cells (Solter, D., Nat Rev Genet, 7:319-327 (2006), nic germ (EG), or
ES cells (Zwaka and Thomson, Development, 132227-2233 (2005)) share many features with the parental
embryonic cells, ting that the pluripotent phenotype is dominant in such fusion products. As with
mouse (Tada et al., Curr Biol, 11:1553-1558 (2001)), human ES cells have the potential to reprogram
somatic nuclei after fusion (Cowan et al., Science, 309:1369-1373(2005)); Yu et al., Science, 31819174920
(2006)). Activation of silent pluripotency markers such as Oct4 or vation of the inactive somatic X
chromosome ed molecular ce for reprogramming of the somatic genome in the hybrid cells. It
has been suggested that DNA ation is ial for the activation of pluripotency markers, which is first
observed 2 days after fusion (Do and Scholer, Stem Cells, 22:941~949 (2004)), and that forced
overexpression of Nanog in ES cells promotes pluripotency when fused with neural stem cells (Silva et al.,
Nature, 441 :997-1 001 (2006)).
Culture-Induced Reprogmmmigg
Pluripotent cells have been derived from embryonic sources such as blastomcres and the inner cell
mass (ICM) of the blastocyst (ES , the epiblast (EpiSC cells), primordial germ cells (EG cells), and
postnatal togonial stem cells (“maGSCsrn” “ES-like” cells). The ing pluripotent cells, along
with their donor cell/tissue is as s: parthogenctic ES cells are derived from murine oocytes
(Narasimha et al., Curr Biol, 72881-884 (1997)); embryonic stem cells have been derived from blastomcres
(Wakayama et al., Stem Cells, 25:986-993 (2007)); inner cell mass cells (source not applicable) (Eggan et
al., Nature, 428:44-49 (2004)); embryonic germ and embryonal carcinoma cells have been derived from
primordial germ cells (Matsui et al., Cell, 70:841-847 ); GMCS, maSSC, and MASC have been
derived from spermatogonial stem cells (Guan et al., Nature, 440:1199—1203 (2006); Kanatsu—Shinohara et
al., Cell, 119:1001—1012 (2004); and l et al., Nature, 449:346-350 (2007)); EpiSC cells are derived
from epiblasts (Brons et al., Nature, 448:191—195 (2007); Tesar et al., Nature, 448:196-199(2007));
parthogenetic ES cells have been derived from human s (Cibelli et al., Science, 295L819 (2002);
Revazova et al., Cloning Stem Cells, 9:432-449 (2007)); human ES cells have been derived from human
blastocysts (Thomson et al., Science, 282:1145-1147 (1998)); MAPC have been d from bone marrow
(Jiang et al., Nature, 418:41-49 (2002); Phinney and Prodtop, Stem Cells, 25 :2896-2902 ); cord blood
cells (derived from cord blood) (van de Ven et al., Exp Hematol. 35:1753-1765 (2007)); neurosphere derived
cells derived from neural cell (Clarke et al., Science, 288: 663 (2000)). Donor cells from the germ cell
lineage such as PGCs or spermatogonial stem cells are knovm to be unipotent in viva, but it has been shown
that pluripotent ES-like cells (Kanatsu-Shinohara et al., Cell, 119:1001-1012 (2004) or maGSCs (Guan et
al., Nature, 440:1199-1203 (2006), can be isolated after prolonged in virra culture. While most of these
pluripotent cell types were capable of in vitro differentiation and teratoma formation, only ES, EG, EC, and
the togonial stem erived maGCSs or ES-like cells were pluripotent by more stringent criteria, as
they were able to form postnatal chimeras and contribute to the germliuc. Recently, multipotcnt adult
W0 68295
spermatogonial stem cells (MASCs) were derived from testicular spermatogonial stem cells of adult mice,
and these cells had an expression profile different from that of ES cells (Seandel et al., Nature, 449:346-350
(2007)) but r to EpiSC cells, which were derived from the epiblast of postimplantation mouse embryos
(Brons et al., Nature, 448:191-195 (2007); Tesar et al., Nature, 448:196-199 ).
Reprommming by Defined Transcription Factors
] Takahashi and Yamanaka have reported reprogramming somatic cells back to an ES-like state
ashi and Yamanaka, Cell, 126:663-676 (2006)). They successfully reprogrammed mouse embryonic
fibroblasts (MEFs) and adult fibroblasts to pluripotent ES-like cells after viral-mediated transduction of the
four transcription factors Oct4, 50x2, c—myc, and K1f4 followed by selection for activation of the Oct4 target
gene Fbx15 (Figure 2A). Cells that had activated Fbx15 were coined iPS (induced pluripotent stem) cells
and were shown to be pluripotent by their ability to form teratomas, although the were unable to generate
live chimeras. This pluripotent state was ent on the' continuous viral sion of the transduced
Oct4 and 80x2 genes, whereas the endogenous Oct4 andNanog genes were either not expressed or were
expressed at a lower level than in ES cells, and their respective promoters were found to be largely
methylated. This is consistent with the conclusion that the FbxlS-iPS cells did not correspond to ES cells
but may have represented an incomplete state of reprogramming. While genetic experiments had established
that Oct4 and 80x2 are essential for pluripotency ers and Smith, Oncogene, 23:7150-7160 (2004);
Ivanona et al., Nature, 4425330538 (2006); Masui et al., Nat Cell Biol, 9:625-635 (2007)), the role of the
two oncogenes cwmyc and Klf4 in ranuning is less clear. Some of these oncogenes may, in fact, be
dispensable for reprogramming, as both mouse and human iPS cells have been obtained in the absence of c-
myc transduction, although with low efficiency (Nakagawa et al., Nat Biotechnol, 26:191-106 ;
Weming et al,, Nature, 4482318-324 (2008); Yu et al., Science, 318: 1917-1920 (2007)).
MAPC
Human MAPCs are described in US. Patent 7,015,037. MAPCs have been identified in other
mammals. Murine MAPCs, for example, are also described in US. Patent 7,015,037. Rat MAPCs are also
described in US. Patent No. 289.
These references are incorporated by nce for describing MAPCs first isolated by Catherine
Verfaillie.
Isolation and Growth of MAPCs
[001641 Methods of MAPC isolation are known in the art. See, for e, US. Patent 7,015,037, and
these methods. along with the characterization (phenotype) of MAPCs, are incorporated herein by reference.
MAPCs can be isolated from multiple sources, including, but not limited to, bone marrow, placenta,
W0 2012/168295 PCT/E92012/060690
umbilical cord and cord blood, muscle, brain, liver, spinal cord, blood or skin, It is, therefore, possible to
obtain bone marrow aspirates, brain or liver biopsies, and other organs, and isolate the cells using positive or
ve selection techniques available to those of skill in the art, relying upon the genes that are expressed
(or not expressed) in these cells (e.g., by functional or morphological assays such as those disclosed in the
above-referenced applications, which have been incorporated herein by reference).
] MAPCs have also been obtained my modified methods described in Breyer et al., EXperimental
Hematology, 34:1596-1601 (2006) and Submmanian et al., Cellular Programing and Reprogramming:
Methods and Protocols; S. Ding (ed), Methods in Molecular Biology, 636:55-78 (2010), incorporated by
reference for these methods.
MAPCs from Human Bone Marrow as Described in US. Patent 037
MAPCs do not express the common leukocyte antigen CD45 or erythroblast specific glycophorin—
A (Gly-A). The mixed population of cells was subjected to a Ficoll e separation. The cells were then
subjected to negative selection using anti—CD45 and anti-Gly—A antibodies, depleting the population of
CD4S‘: and Gly-A‘; cells, and the remaining approximately 0.1% of marrow clear cells were then
recovered. Cells could also be plated in fibronectin-coated Wells and cultured as bed below for 2-4
weeks to deplete the cells of CD45+ and Gly-A+ cells. In cultures of nt bone marrow cells, many
nt stromal cells undergo replicative senescence around cell doubling 30 and a more homogenous
population of cells continues to expand and maintains long telomeres.
Alternatively, ve selection could be used to e cells via a combination of cell-specific
markers. Both positive and negative selection techniques are available to those of skill in the an, and
are also available
numerous monoclonal and polyclonal antibodies suitable for negative selection purposes
in the art (see, for example, Leukocyte Typing V, Schlossman, et al., Eds. (1995) Oxford University Press)
and are commercially available from a number of sources.
Techniques for mammalian cell separation from a e of cell populations have also been
described by Schwartz, er al., in U. S. Patent No. 5,759,793 (magnetic separation), Basch et. al., 1983
(immunoaffinity chromatography), and Wysocki and Sato, 1978 (fluorescence-activated cell sorting).
Cells may be cultured in low-serum or serum—free culture medium. Serum-free medium used to
culture MAPCs is described in U.S. Patent 7,015,037. Commonly-used growth factors include but are not
limited to platelet—derived growth factor and mal growth factor. See, for example, US. Patent. Nos,
7,169,610; 7,109,032; 7,037,721; 6,617,161; 159; 6.372,210;6,224,860; 6,037,174; 5,908,782;
951; 5,397,706; and 4,657,866; all orated by reference for ng growing cells in serum-free
medium.
W0 20121168295
Additional Culture Methods
In additional experiments the y at which MAPCs are cultured can vary from about 100
cells/cm: or about 150 cells/ch to about 10,000 crnz, including about 200 cons/coo2 to about 1500
celis/cmz to about 2000 cells/m2. The density can vary between species. Additionally, optimal density can
vary depending on e conditions and source of cells. It is within the skill of the ordinary artisan to
determine the optimal density for a given set of culture conditions and cells.
] Also, effective atmospheric oxygen concentrations of less than about 10%, including about 1-5%
and, especially, 3—5%, can be used at any time during the isolation, growth and differentiation of MAPCs in
culture.
Cells may be cultured under various serum concentrations, e.g., about 2—20%. Fetal bovine serum
may be used. Higher serum may be used in combination with lower oxygen tensions, for example, about 15-
%. Cells need not be selected prior to adherence to culture dishes. For example, after a Ficoll gradient,
cells can be directly plated, e.g., 250,000-500,000/cm2. Adherent colonies can be picked, possibly pooled,
and expanded.
In one embodiment, used in the experimental procedures in the Examples, high serum (around 15-
%) and low oxygen (around 3-5%) conditions Were used for the cell culture. Specifically, adherent cells
from colonies were plated and passaged at densities of about WOO-2300 cm2 in 18% serum and 3%
oxygen (with PDGF and EGF).
In an embodiment specific for MAPCs, supplements are cellular factors or ents that allow
MAPCs to retain the ability to entiate into cell types of more than one embryonic lineage, such as all
three es. This may be ted by the expression of specific markers of the undifferentiated state,
such as Oct 3/4 (Oct 3A) and/or markers of high expansion capacity, such as tase.
Cell Culture
For all the components listed below, see US. 7,015,037, which is incorporated by reference for
teaching these components.
In general, cells useful for the invention can be ined and expanded in culture medium that
is available and well—known in the art. Also contemplated is supplementation of cell e medium with
mammalian sera, Additional supplements can also be used advantageously to supply the cells with the
necessary trace elements for optimal growth and ion. Hormones can also be advantageously used in
cell culture. Lipids and lipid carriers can also be used to supplement cell culture media, depending on the
type of cell and the fate of the differentiated cell. Also contemplated is the use of feeder cell layers.
Stem cells often require additional factors that encourage their attachment to a solid support, such
as laminins, type I and type II collagens, chondroitin sulfate, fibronectin, “superfibronectin” and fibronectin-
like polymers, gelatin, poly—D and poly-L—lysine, thrombospondin and vitronectin. Other suitable coating
materials, based on or composed of basal membrane-derived protein mixtures, can be used. Some of these
are commercially available, such as Matrigel. Coatings may use extracellular matrix proteins, and suitable
derivatives thereof, as well as es of these proteins. One embodiment of the present invention utilizes
fibronectin. See, for example, Ohashi et al., Nature Medicine, 13:880-885 (2007); Matsumoto et al., J
Bioscience and Bioengineering, 105:350-354 (2008); c et al., Cell Stem Cell, 3:369-381 (2008); Chua
et 8.1., Biomaterials, 7-2547 ; Drobinskaya et al., Stem Cells, 262245-2256 (2008); Dvir—
Ginzberg et al., FASEB J , 22:1440—1449 (2008); Turner et 211., J Biomed Mater Res Part B: App! Biomater,
6-168 ; and Miyazawa et al., l of Gastroenterology and logy, 22:1959-1964
(2007)).
Once established in culture, cells can be used fresh or frozen and stored as frozen stocks, using,
for example, DMEM with 20%—40% FCS and 10% DMSO. In one embodiment, 20% FCS is used. Other
methods for preparing frozen stocks for ed cells are also ble to those of skill in the art.
For the purposes of this application, the onal culture methods as well as the other culture
methods also apply to the bioreactor methods, with respect to the medium components and conditions
described above. As an example, in an exemplified embodiment, the oxygen concentration is 5%, serum is
about 19% and both EGF and PDGF are added to the medium
Pharmaceutical Formulations
US. 7,015,037 is incorporated by reference for ng pharmaceutical formulations. In certain
embodiments, the cell populations are present within a composition adapted for and suitable for delivery,
i.e., physiologically compatible.
In some embodiments the purity of the cells (or conditioned medium) for stration to a
subject is about 100% (substantially homogeneous). In other ments it is 95% to 100%. In some
embodiments it is 85% to 95%. Particularly, in the case of admixtures with other cells, the percentage can
be about 10%-15%, 15%-20%, 20%-25%, 25%«30%, 30%-3S%, 35%-40%, 40%—4S%, 45%-50%, 60%-
70%, 70%-80%, 80%-90%, or 90%—95%. Or isolation/purity can be sed in terms of cell doublings
where the cells have one, for example, 10—20, 20-30, 30-40, 40-50 or more cell doublings.
The choice of formulation for administering the cells for a given application will depend on a
variety of s. Prominent among these will be the species of subject, the nature of the condition being
treated. its state and distribution in the subject, the nature of other therapies and agents that are being
administered, the optimum route for administration, survivability via the route, the dosing regimen, and
PCT/EPZ012/060690
other factors that will be apparent to those skilled in the art. For instance, the choice of suitable carriers and
other additives will depend on the exact route of administration and the nature of the particular dosage form.
Final formulations of the s suspension of cells/medium will typically involve adjusting the
ionic th of the suspension to isotonicity (i.e., about 0.] to 0.2) and to logical pH (i.e., about pH
6.8 to 7.5). The final ation will also typically contain a fluid lubricant.
In some ments, cells/medium are formulated in a unit dosage injectable form, such as a
solution, suspension, or emulsion. Pharmaceutical formulations le for injection of cells/medium
typically are e aqueous solutions and dispersions. Carriers for injectable ations can be a solvent
or dispersing medium containing, for example, water, , phosphate buffered saline, polyol (for example,
ol. propylene glycol, liquid polyethylene glycol, and the like), and suitable mixtures thereof.
The skilled artisan can readily determine the amount of cells and optional ves, vehicles,
and/or carrier in compositions to be administered in methods of the invention. Typically, any additives (in
on to the cells) are present in an amount of 0.001 to 50 wt % in solution, such as in phosphate buffered
saline. The active ingredient is present in the order of micrograms to milligrams, such as about 0.0001 to
about 5 wt "At, preferably about 0.0001 to about 1 wt %, most preferably about 0.000] to about 0.05 wt % or
about 0.001 to about 20 wt %, preferably about 0.0] to about 10 wt %, and most preferably about 0.05 to
about 5 wt %.
EXAMPLES
Example 1. Expanding MultiStem From a Cell Bank By Means OfA Hollow Fiber ctor Cell
Expansion System
A cell expansion system, essentially as described in US. 2008/0220523 and Antwilcr et al., was
used to expand an input population of MultiStem, which is a ntially homogeneous population. The
system was designated Quantum CES. It provided a bench—top expansion system that is particularly useful
for autologous expansion. (But it is also useful for allogeneic expansion.) Based on the results shown in this
application, greater than 108 cells can be obtained from a single donor.
Mufti-Stem was thawed after having been stored in a frozen cell bank. For two experiments, 10 x
106 MultiStem were inoculated into a continuous flow bioreaotor with an internal fluid volume of 184 ml and
an external fluid volume of 303 ml, containing 1.1 x 104 hollow fibers with a total surface area (intrau
capillary) of approximately 2.1 in2 (3255in2), a wall thickness of 50 pm. inner diameter of 215 um, and total
length of 295 mm (average 30 mm per fiber, range of 10-50 nun). Pore size had an approximate cutoff of 16
kDa. The cells adhered to the inside of the hollow fibers. Cells were cultured for six days. 752 x 106, 753 x
W0 2012/168295 PCTIEP2012/060690
106 and 782 x 106 cells were produced in three independent experiments starting from the same seeding
stock.
The flow rate could be variable but generally sed as the cells proliferated so that the
nutrients were provided in sufficient amounts and the waste products were d in sufficient amounts.
In general, the flow rate can be increased around ten times. However, this parameter was adjusted by
monitoring the waste ts, such as lactate and glucose levels, in the .
The wall material was a composite of PA/PAES/PVP.
Also, in this particular embodiment, the fibers were coated with fibronectin.
For established cells, that is those that were derived from a previously isolated, expanded,
ntially purified culture, 5 mg of fibronectin is used and the coating is done overnight. Then the
coating is washed out and replaced by . After seeding, the cells are attached for 24 hours with no
flow through the intracellular loop. After that the feed rate is d at about 0.] ml per minute. Based on
the lactate level and on the doubling rates ofthe cells, the feed rate is doubled imately every 24 hours.
In the first three days the ors attempted to keep the lactate level around 0.5 g/l. The last three days it is
kept at around 1 g/l with a maximum of 1.5 g/l. On the last day (i.e. when the cells are expanded to their
maximum) the feed rate is about 3 ml/minute.
Cells are harvested using about 200 ml 2.5% trypsin with a 2.5 minute incubation period and a
harvest volume of about 500 ml.
When a bone marrow aspirate is used, the intracapillary surface is coated with about. 10 mg of
fibronectin with a 48 hour attachment phase. The feed rate is adjusted so that. if the lactate level goes up to
0.4 to 0.5 g/l, the feed rate is doubled. The rate generally is not as high compared to a culture starting from
cells that have been ished. In one experiment, about 25-30 ml of bone marrow aspirate was used to
e about 4x 106 cells from total BMMC. For that, bone marrow was subjected to a ficoll gradient to
remove non-nucleated cells.
Details are found in Figure 5. The flow scheme is comprised of 2 loops: the intracapillary (1C)
and extracapillary (EC) loop. The [C loop has 3 inlet lines: cell line, reagent line and IC media line. Bags
are attached to these lines for adding cells. coating agent, trypsin and media. Each line is controlled by a
valve, which has 2 positions, open or close. The inlet rate is controlled by the 1C inlet pump (1). Circulation
within the system is controlled by the IC circulation pump (2). The IC circuit contains 150 ml. The EC loop
has 2 inlet lines: Wash (solution) and EC media line. Bags are ed to these lines for washing with PBS
and adding medium to the EC loop. The EC inlet rate is controlled by the EC inlet pump (3) and the
circulation within this circuit by the EC circulation pump (4). In the EC loop an oxygenator is present. This
oxygenator is attached to an external gas cylinder (for MultiStem this is 90% N2; 5% 02; 5% C02) and
maintains the gas concentrations for the EC . The IC medium is brought to equilibrium because of
perfusion of the gases through the membrane in the bioreactor. The EC circuit contains around 250 m1.
There are 2 ways for solutions/cells to leave the system: in the waste bag or the harvest bag. The IC as well
as the EC loop have a connection to the waste bag which is controlled by a valve. The harvest bag only as a
connection with the IC loop and is also controlled by a valve.
] The input population and the output tion were compared. Specifically, the input population
was assessed for gene expression of certain selected genes and this was compared with the output
population. In addition, logy and ploidy were compared. The output population was substantially
identical to the input population with respect to the measured parameters.
Example 2. ing MultiStem From Bone Marrow in a Hollow Fiber Bioreactor Cell Expansion System
The cell expansion system described above was used to produce tem from bone marrow
clear cells. The expansion results are shown in Figure 6. In one possible regimen, ng from a
bone marrow aspirate, it is possible to create a MultiStem master cell bank within 17 days. This takes one
run from bone marrow to 15 population doublings and an expansion run to this harvest to reach a population
doubling of 18.5 and an average of ten runs to create a master cell bank (200 vials of 20 million cells).
These 200 vials can then be used to create working cell banks. The schematic is shown in Figure 7.
However, the master cell bank could be increased or decreased, such as up to d more cells or down to
-fold less cells.
] The output cells, following expansion, had the immunomodulatory properties associated with
MultiStem and expressed telomerase.
Figure 9 provides an overview of an expansion embodiment with the closed system, continuous
perfusion, hollow fiber bioreactor. The specific summary of the procedure is as follows:
1) RE PROVIDES AUTOMATED PROCEDURES
2) SETUP
2a) Load and prime disposable set
2b) Coat the bioreactor membrane with fibronectin (overnight coating)
2c) Replace PBS in both loops by media
2d) Medium ioning
2e) Load the cells and let them attach (overnight attachment)
2f) Perform a washout to remove non adherent cells
2g) Continuously feed cells with medium
2h) Adjust feed rate ing to lactate generation and glucose consumption
2i) Harvest with Trypsin/EDTA
3 WORKLOAD
3a) 1 run takes 6 working hours
-and estimate of 2 to 3 hours if everything would already be available in bags
The discussion of documents, acts, materials, devices, articles and the like is included in this
specification solely for the e of providing a context for the present ion. It is not suggested or
represented that any or all of these matters formed part of the prior art base or were common general
knowledge in the field nt to the present invention as it existed before the priority date of each claim of
this application.
] Throughout the description and claims of this specification, the word “comprise” and variations of
the word, such as “comprising” and “comprises”, is not intended to exclude other additives, components,
integers or steps.
Claims (13)
1. A method of expanding cells ex vivo, the method comprising the steps of: a) seeding the cells on a hollow fiber substrate so that the cells adhere to the substrate; b) expanding the adhered cells on the ate; and 5 c) removing the expanded cells from the substrate, wherein the cells are non-embryonic stem, non-germ cells, wherein the cells express telomerase, are not transformed, and have a normal karotype.
2. The method of claim 1 further comprising d) reseeding the removed cells on the same or ent substrate; and e) repeating steps b) - d) until a desired number of expanded cells is reached.
3. The method of claim l in which the hollow fiber substrate is in a closed continuous perfusion bioreactor.
4. The method of any one of claims 1 to 3 in which the cells are expanded about 10-100 fold. 15
5. The method of claims 1 to 4, wherein the hollow fiber is coated.
6. The method of claim 5, wherein the coating is fibronectin.
7. The method of claim 6, wherein the wall material in fiber is PA/PAES/PVP.
8. The method of claims 1 to 7, wherein the cells in step (a) comprise a substantially homogeneous population.
9. The method of claims 1 to 7, wherein step (a) comprises seeding cells from a tissue, the tissue selected 25 from bone , umbilical cord blood, umbilical cord matrix, peripheral blood, placenta, placental blood, muscle, brain, kidney, or other solid .
10. The method of claim 1, wherein the non-embryonic stem, rm cells further express one or more of oct4, rex-1, rox-1, or sox-2.
11. The method of claim 1 and claim 10, wherein the non-embryonic stem, non-germ cells can entiate into at least one cell type of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages. 35
12. The method of claim 11, wherein the non-embryonic stem, non-germ cells that can entiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages.
13. A medicament formulated for administration to a subject, the medicament ing cells expanded in accordance of any one of claims 1 to 12.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161493737P | 2011-06-06 | 2011-06-06 | |
US61/493,737 | 2011-06-06 | ||
PCT/EP2012/060690 WO2012168295A1 (en) | 2011-06-06 | 2012-06-06 | Expansion of stem cells in hollow fiber bioreactors |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ618651A NZ618651A (en) | 2015-07-31 |
NZ618651B2 true NZ618651B2 (en) | 2015-11-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2718416B1 (en) | Expansion of stem cells in hollow fiber bioreactors | |
AU2012266404A1 (en) | Expansion of stem cells in hollow fiber bioreactors | |
US20230131225A1 (en) | Modulation of Microglia Activation | |
WO2006095480A1 (en) | Cell culture chamber | |
JP2014060991A (en) | Method of culturing stem cells using inner lumen of porous hollow fiber | |
ES2753323T3 (en) | Cell therapy for myelodysplastic syndromes | |
NZ618651B2 (en) | Expansion of stem cells in hollow fiber bioreactors | |
CN113201486A (en) | Method and apparatus for generating oocytes with increased oocyte cytoplasm volume for in vitro fertilization procedures using non-invasive cell transfer | |
BR112013031368B1 (en) | METHOD OF EXPANDING EX VIVO CELLS | |
Morini et al. | Liver tissue engineering | |
US20230113241A1 (en) | Automated method for preparing keratinocytes | |
López et al. | Isolation and Characterization of Fetal Liver Hematopoietic Stem Cells | |
Ulrich et al. | Pancreatic differentiation from human pluripotent stem cells | |
Espinha | Bioprocess engineering of induced pluripotent stem cells for application in cell therapy and pre-clinical research | |
Ka et al. | STEM CELLS–THE ULTIMATE BODY REPAIR KIT | |
US20080113400A1 (en) | Methods and Devices for Culturing Stem Cells | |
Mossa et al. | SLAS Discovery | |
WO2015172207A1 (en) | Mesodermal progenitor cells |